TW201831489A - 布魯頓氏酪胺酸激酶之抑制劑 - Google Patents
布魯頓氏酪胺酸激酶之抑制劑 Download PDFInfo
- Publication number
- TW201831489A TW201831489A TW107106216A TW107106216A TW201831489A TW 201831489 A TW201831489 A TW 201831489A TW 107106216 A TW107106216 A TW 107106216A TW 107106216 A TW107106216 A TW 107106216A TW 201831489 A TW201831489 A TW 201831489A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- scope
- patent application
- salt
- item
- Prior art date
Links
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title claims description 28
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title claims 4
- 239000003112 inhibitor Substances 0.000 title description 36
- 239000000203 mixture Substances 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 78
- 150000001875 compounds Chemical class 0.000 claims description 377
- 150000003839 salts Chemical class 0.000 claims description 93
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 77
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 61
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 56
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 claims description 17
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 17
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 14
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 14
- 239000011343 solid material Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 239000001384 succinic acid Substances 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 239000001530 fumaric acid Substances 0.000 claims description 8
- 235000006408 oxalic acid Nutrition 0.000 claims description 7
- 150000003890 succinate salts Chemical class 0.000 claims description 7
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 6
- 150000003891 oxalate salts Chemical class 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- DSGUSEBCDAKBCM-UHFFFAOYSA-N ethane-1,2-disulfonic acid;dihydrate Chemical compound O.O.OS(=O)(=O)CCS(O)(=O)=O DSGUSEBCDAKBCM-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 150000004683 dihydrates Chemical class 0.000 claims description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 3
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims 5
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- DPKGTLUCCMJBQI-UHFFFAOYSA-N ethane-1,2-disulfonic acid;hydrate Chemical compound O.OS(=O)(=O)CCS(O)(=O)=O DPKGTLUCCMJBQI-UHFFFAOYSA-N 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 22
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 75
- -1 hemiethanesulfonate Chemical compound 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 54
- 238000002411 thermogravimetry Methods 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 28
- 238000000113 differential scanning calorimetry Methods 0.000 description 26
- 102000005962 receptors Human genes 0.000 description 25
- 108020003175 receptors Proteins 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 24
- 238000001757 thermogravimetry curve Methods 0.000 description 23
- 229940124291 BTK inhibitor Drugs 0.000 description 22
- 239000003446 ligand Substances 0.000 description 22
- 238000001179 sorption measurement Methods 0.000 description 22
- 239000007789 gas Substances 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 108091000080 Phosphotransferase Proteins 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 102000020233 phosphotransferase Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 12
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 11
- 229910052805 deuterium Inorganic materials 0.000 description 11
- 239000007937 lozenge Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 102000001253 Protein Kinase Human genes 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 108060006633 protein kinase Proteins 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 8
- 229940011051 isopropyl acetate Drugs 0.000 description 8
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 238000009434 installation Methods 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 238000013456 study Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 230000003510 anti-fibrotic effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 108010024121 Janus Kinases Proteins 0.000 description 4
- 102000015617 Janus Kinases Human genes 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 108700040121 Protein Methyltransferases Proteins 0.000 description 4
- 102000055027 Protein Methyltransferases Human genes 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005496 eutectics Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 description 4
- 229960004961 mechlorethamine Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229940127557 pharmaceutical product Drugs 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 3
- 108010078554 Aromatase Proteins 0.000 description 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 3
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 3
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 3
- 102100022337 Integrin alpha-V Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 3
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- 101710190034 Trophoblast glycoprotein Proteins 0.000 description 3
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 3
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229950010482 alpelisib Drugs 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002271 cobimetinib Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- GFUITADOEPNRML-SJORKVTESA-N (2r,3r)-3-(cyclopentylmethyl)-n-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1C[C@H](C(=O)NO)[C@H](C(=O)N1CCCCC1)CC1CCCC1 GFUITADOEPNRML-SJORKVTESA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 description 2
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 2
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108091005625 BRD4 Proteins 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 102100038495 Bile acid receptor Human genes 0.000 description 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 108090000197 Clusterin Proteins 0.000 description 2
- 102100032887 Clusterin Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
- 108010074311 Corticotropin Receptors Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 2
- 102100030011 Endoribonuclease Human genes 0.000 description 2
- 101710199605 Endoribonuclease Proteins 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 description 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 2
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 2
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 101000939246 Homo sapiens SUMO-conjugating enzyme UBC9 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 101000588553 Homo sapiens Serine/threonine-protein kinase Nek9 Proteins 0.000 description 2
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 2
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 2
- 108030003815 Inositol 3-kinases Proteins 0.000 description 2
- 102100032818 Integrin alpha-4 Human genes 0.000 description 2
- 101710123022 Integrin alpha-V Proteins 0.000 description 2
- 108010041012 Integrin alpha4 Proteins 0.000 description 2
- 102000012355 Integrin beta1 Human genes 0.000 description 2
- 108010022222 Integrin beta1 Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 101710126949 Lysin Proteins 0.000 description 2
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 2
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 2
- 102100021949 Lysyl oxidase homolog 3 Human genes 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 2
- 101710147239 Metalloreductase STEAP1 Proteins 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 2
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 102100036197 Prosaposin Human genes 0.000 description 2
- 101710152403 Prosaposin Proteins 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 102100032420 Protein S100-A9 Human genes 0.000 description 2
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 2
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 2
- 101150077555 Ret gene Proteins 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 description 2
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 102100031398 Serine/threonine-protein kinase Nek9 Human genes 0.000 description 2
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 description 2
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 102000012803 ephrin Human genes 0.000 description 2
- 108060002566 ephrin Proteins 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 229950011548 fadrozole Drugs 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960004421 formestane Drugs 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229940126401 izorlisib Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229950002142 minretumomab Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 2
- TTZSNFLLYPYKIL-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide Chemical compound CN(C)CCNS(=O)(=O)CC1=CC=CC(NC=2N=C(OC=3C=C4C=C(C)NC4=CC=3)C=CN=2)=C1 TTZSNFLLYPYKIL-UHFFFAOYSA-N 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229950011410 pacritinib Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108010001062 polysaccharide-K Proteins 0.000 description 2
- 229940034049 polysaccharide-k Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 2
- 229950003618 pracinostat Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 description 2
- 229950002821 resminostat Drugs 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 1
- URLVCROWVOSNPT-XOTOMLERSA-N (2s)-4-[(13r)-13-hydroxy-13-[(2r,5r)-5-[(2r,5r)-5-[(1r)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]tridecyl]-2-methyl-2h-furan-5-one Chemical compound O1[C@@H]([C@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 URLVCROWVOSNPT-XOTOMLERSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- OYYVWNDMOQPMGE-SDQBBNPISA-N (5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound OC1=CC(F)=CC=C1C(O1)=CC=C1\C=C/1C(=O)NC(=O)S\1 OYYVWNDMOQPMGE-SDQBBNPISA-N 0.000 description 1
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical compound COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- SXCIMUIAZXOVIR-PUCKCBAPSA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 SXCIMUIAZXOVIR-PUCKCBAPSA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- YMJUYKGULHVQPS-UHFFFAOYSA-N 2,4-dioxo-1h-pyrimidine-6-carboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)C1=CC(=O)NC(=O)N1 YMJUYKGULHVQPS-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- VLIUIBXPEDFJRF-UHFFFAOYSA-N 2-(n-(2-chlorophenyl)anilino)-n-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C(=CC=CC=1)Cl)C1=CC=CC=C1 VLIUIBXPEDFJRF-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 1
- MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 description 1
- JWQOJVOKBAAAAR-UHFFFAOYSA-N 2-[[7-(3,4-dimethoxyphenyl)-5-imidazo[1,2-c]pyrimidinyl]amino]-3-pyridinecarboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=NC=CN2C(NC=2C(=CC=CN=2)C(N)=O)=N1 JWQOJVOKBAAAAR-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- AQLUWRRQWYYZBA-UHFFFAOYSA-N 2-amino-5-methyl-5-sulfanylhexanoic acid Chemical compound CC(C)(S)CCC(N)C(O)=O AQLUWRRQWYYZBA-UHFFFAOYSA-N 0.000 description 1
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 description 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 1
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 description 1
- IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical compound NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- NYPGBHKJFKQTIY-TYYBGVCCSA-N 2-cyanoethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound NCCC#N.OC(=O)\C=C\C(O)=O NYPGBHKJFKQTIY-TYYBGVCCSA-N 0.000 description 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 1
- LNCCBHFAHILMCT-UHFFFAOYSA-N 2-n,4-n,6-n-triethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCNC1=NC(NCC)=NC(NCC)=N1 LNCCBHFAHILMCT-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- ALYOQPBWHZJZLF-UHFFFAOYSA-N 2-nitrobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)[N+]([O-])=O ALYOQPBWHZJZLF-UHFFFAOYSA-N 0.000 description 1
- VZUKEVFHSPMCSH-UHFFFAOYSA-N 2-nitroethanamine Chemical compound NCC[N+]([O-])=O VZUKEVFHSPMCSH-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- UJIAQDJKSXQLIT-UHFFFAOYSA-N 3-[2,4-diamino-7-(3-hydroxyphenyl)-6-pteridinyl]phenol Chemical compound C=1C=CC(O)=CC=1C1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC(O)=C1 UJIAQDJKSXQLIT-UHFFFAOYSA-N 0.000 description 1
- ZTGQZSKPSJUEBU-UHFFFAOYSA-N 3-bromopropan-1-amine Chemical compound NCCCBr ZTGQZSKPSJUEBU-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- BOCATKBAKISRLA-UHFFFAOYSA-N 4-propyl-5-pyridin-4-yl-3h-1,3-oxazol-2-one Chemical compound N1C(=O)OC(C=2C=CN=CC=2)=C1CCC BOCATKBAKISRLA-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
- XSMSNFMDVXXHGJ-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XSMSNFMDVXXHGJ-UHFFFAOYSA-N 0.000 description 1
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- NHHQJBCNYHBUSI-UHFFFAOYSA-N 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 NHHQJBCNYHBUSI-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- NJIAKNWTIVDSDA-FQEVSTJZSA-N 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-n-[[(2s)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine Chemical compound C1CN(S(=O)(=O)C)CCC1C1=CC=C(C=2N=C(NC[C@H]3OCCNC3)C3=NC=CN=C3C=2)C=C1 NJIAKNWTIVDSDA-FQEVSTJZSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
- YPDSIEMYVQERLJ-UHFFFAOYSA-N 8-Hydroxypurine Chemical compound C1=NC=C2NC(O)=NC2=N1 YPDSIEMYVQERLJ-UHFFFAOYSA-N 0.000 description 1
- LMJFJIDLEAWOQJ-CQSZACIVSA-N 8-[(1r)-1-(3,5-difluoroanilino)ethyl]-n,n-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide Chemical compound N([C@H](C)C=1C2=C(C(C=C(O2)N2CCOCC2)=O)C=C(C=1)C(=O)N(C)C)C1=CC(F)=CC(F)=C1 LMJFJIDLEAWOQJ-CQSZACIVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 108060000255 AIM2 Proteins 0.000 description 1
- 229960005531 AMG 319 Drugs 0.000 description 1
- BBUVDDPUURMFOX-SAABIXHNSA-N AMG-925 Chemical compound C1C[C@@H](C)CC[C@@H]1N1C2=NC(NC=3N=C4CCN(CC4=CC=3)C(=O)CO)=NC=C2C2=CC=NC=C21 BBUVDDPUURMFOX-SAABIXHNSA-N 0.000 description 1
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 1
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
- 241000714175 Abelson murine leukemia virus Species 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 101710190443 Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 101001010152 Aplysia californica Probable glutathione transferase Proteins 0.000 description 1
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100029361 Aromatase Human genes 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 108050001413 B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 108010064528 Basigin Proteins 0.000 description 1
- 102100032412 Basigin Human genes 0.000 description 1
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 description 1
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 1
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- CRRRRSWDPPGVSR-MMFRDWCLSA-N C(CC[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2CNC=3N=C(N)NC(=O)C3N2)C=C1)(=O)O.C(=N)N Chemical compound C(CC[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2CNC=3N=C(N)NC(=O)C3N2)C=C1)(=O)O.C(=N)N CRRRRSWDPPGVSR-MMFRDWCLSA-N 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150093750 CD40LG gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 101150088890 CD70 gene Proteins 0.000 description 1
- 101150001392 CD79B gene Proteins 0.000 description 1
- 108060001253 CD99 Proteins 0.000 description 1
- 102000024905 CD99 Human genes 0.000 description 1
- REBZXFCGRDGTSF-UHFFFAOYSA-N CN(CC(Cl)Cl)O.Cl Chemical compound CN(CC(Cl)Cl)O.Cl REBZXFCGRDGTSF-UHFFFAOYSA-N 0.000 description 1
- 102100028879 COP9 signalosome complex subunit 8 Human genes 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101100498819 Caenorhabditis elegans ddr-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 1
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100037677 Cell surface hyaluronidase Human genes 0.000 description 1
- 101710125063 Cell surface hyaluronidase Proteins 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 241000131500 Chionoecetes opilio Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 101000573882 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP3 Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000008954 Copper amine oxidases Human genes 0.000 description 1
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 description 1
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 description 1
- 101100297652 Coturnix japonica PIM3 gene Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108090000404 Cyclin G1 Proteins 0.000 description 1
- 102000004012 Cyclin G1 Human genes 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 description 1
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 101150062301 Ddr2 gene Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
- 108010066455 Dihydrouracil Dehydrogenase (NADP) Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 101100073171 Drosophila melanogaster Kdm2 gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710120808 Elongation factor 1-alpha 2 Proteins 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 108010001687 Enterotoxin Receptors Proteins 0.000 description 1
- 102000000820 Enterotoxin Receptors Human genes 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- ZPLVYYNMRMBNGE-UHFFFAOYSA-N Eponemycin Natural products CC(C)CCCCC(=O)NC(CO)C(=O)NC(CC(C)=C)C(=O)C1(CO)CO1 ZPLVYYNMRMBNGE-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- 108010073922 Estradiol Dehydrogenases Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 101150111025 Furin gene Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 208000021006 GRFoma Diseases 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101710179596 Gene 3 protein Proteins 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101150096895 HSPB1 gene Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101710162034 Homeobox protein NANOG Proteins 0.000 description 1
- 102100031922 Homeobox protein NANOG Human genes 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000916502 Homo sapiens COP9 signalosome complex subunit 8 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101000945335 Homo sapiens Killer cell immunoglobulin-like receptor 2DL5B Proteins 0.000 description 1
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000972796 Homo sapiens NF-kappa-B-activating protein Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 1
- 101100520189 Homo sapiens PKN3 gene Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101001067174 Homo sapiens Plexin-B1 Proteins 0.000 description 1
- 101000923332 Homo sapiens Protein asteroid homolog 1 Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000837903 Homo sapiens TATA box-binding protein-associated factor RNA polymerase I subunit B Proteins 0.000 description 1
- 101100207072 Homo sapiens TNFSF9 gene Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 101000633069 Homo sapiens Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 241000578472 Human endogenous retrovirus H Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 229940043367 IDO1 inhibitor Drugs 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102100033010 Integrin beta-5 Human genes 0.000 description 1
- 102100033011 Integrin beta-6 Human genes 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 102100020990 Interferon lambda-1 Human genes 0.000 description 1
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 1
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 description 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010058031 Joint adhesion Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 101150068332 KIT gene Proteins 0.000 description 1
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 description 1
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 1
- 101710134421 Kinesin-like protein KIF11 Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 102000023108 LH Receptors Human genes 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108700027766 Listeria monocytogenes hlyA Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 102100040788 Lutropin-choriogonadotropic hormone receptor Human genes 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 1
- 101150024200 MAGEC1 gene Proteins 0.000 description 1
- 101150084753 MAGEC2 gene Proteins 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 101150007128 MDM4 gene Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 1
- 101710086716 Metabotropic glutamate receptor 1 Proteins 0.000 description 1
- 101710130205 Metal reductase Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101000900711 Mus musculus GRB2-related adaptor protein 2 Proteins 0.000 description 1
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 description 1
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- CIGRGLYYGIMTOD-GOSISDBHSA-N N1(C=NC=C1)C1=C[C@H](C(CC1)(C)C)N(C1=CC(=C(C#N)C=C1)C(F)(F)F)C Chemical compound N1(C=NC=C1)C1=C[C@H](C(CC1)(C)C)N(C1=CC(=C(C#N)C=C1)C(F)(F)F)C CIGRGLYYGIMTOD-GOSISDBHSA-N 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- 102100022580 NF-kappa-B-activating protein Human genes 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102000002452 NPR3 Human genes 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 108050000302 Neurokinin receptors Proteins 0.000 description 1
- 102000009493 Neurokinin receptors Human genes 0.000 description 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102000005650 Notch Receptors Human genes 0.000 description 1
- 102000001756 Notch2 Receptor Human genes 0.000 description 1
- 108010029751 Notch2 Receptor Proteins 0.000 description 1
- 102000001760 Notch3 Receptor Human genes 0.000 description 1
- 108010029756 Notch3 Receptor Proteins 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 108010027206 Nucleopolyhedrovirus inhibitor of apoptosis Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- XDNKIAZTWLENFU-UHFFFAOYSA-L O.O.O.S(=O)([O-])[O-].[Na+].SCCCC.[Na+] Chemical compound O.O.O.S(=O)([O-])[O-].[Na+].SCCCC.[Na+] XDNKIAZTWLENFU-UHFFFAOYSA-L 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100039467 P3 protein Human genes 0.000 description 1
- 101710117080 P3 protein Proteins 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 101150083673 PKN3 gene Proteins 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 108700028865 Pam2CSK4 acetate and ODN M362 combination Proteins 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102100034384 Plexin-B1 Human genes 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 101710132595 Protein E7 Proteins 0.000 description 1
- 101710156990 Protein S100-A9 Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100032661 Protein asteroid homolog 1 Human genes 0.000 description 1
- 101710092489 Protein kinase 2 Proteins 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108010072960 Proto-Oncogene Proteins c-fyn Proteins 0.000 description 1
- 102000007131 Proto-Oncogene Proteins c-fyn Human genes 0.000 description 1
- 108010046934 Proto-Oncogene Proteins c-hck Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 101150101372 RAF1 gene Proteins 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150020518 RHEB gene Proteins 0.000 description 1
- 108700003853 RON Proteins 0.000 description 1
- 239000005464 Radotinib Substances 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 102000046951 Ras Homolog Enriched in Brain Human genes 0.000 description 1
- 108700019578 Ras Homolog Enriched in Brain Proteins 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100037424 Receptor-type tyrosine-protein phosphatase beta Human genes 0.000 description 1
- 101710101345 Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 description 1
- 102000006438 Receptors for Activated C Kinase Human genes 0.000 description 1
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 1
- 102000002114 Reduced Folate Carrier Human genes 0.000 description 1
- 108050009454 Reduced Folate Carrier Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 108050006676 Retinoblastoma-related proteins Proteins 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- 101150035397 Ros1 gene Proteins 0.000 description 1
- QMZVAEPIILIVIS-UHFFFAOYSA-N S(=O)(=O)(O)O.C(C)(=O)NCCC(CNC(C)=O)S Chemical compound S(=O)(=O)(O)O.C(C)(=O)NCCC(CNC(C)=O)S QMZVAEPIILIVIS-UHFFFAOYSA-N 0.000 description 1
- DMSFTVIKTYZIPJ-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].[Na+].CCCC.[Na+] Chemical compound S(=O)(=O)([O-])[O-].[Na+].CCCC.[Na+] DMSFTVIKTYZIPJ-UHFFFAOYSA-L 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000046202 Sodium-Phosphate Cotransporter Proteins Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 206010041329 Somatostatinoma Diseases 0.000 description 1
- 102000005993 Sphingomyelin synthase Human genes 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 description 1
- 101710163849 Steroid 17-alpha-hydroxylase/17,20 lyase Proteins 0.000 description 1
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 1
- 102100038021 Steryl-sulfatase Human genes 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 101710086566 T-box transcription factor T Proteins 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 101710179381 T-cell differentiation antigen CD6 Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100028546 TATA box-binding protein-associated factor RNA polymerase I subunit B Human genes 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 101150041736 TNFSF9 gene Proteins 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 1
- 102100024547 Tensin-1 Human genes 0.000 description 1
- 108010088950 Tensins Proteins 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 102000002932 Thiolase Human genes 0.000 description 1
- 108060008225 Thiolase Proteins 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101710170091 Transmembrane glycoprotein NMB Proteins 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 101710138398 Tryptophan 5-hydroxylase Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102100036129 Tumor suppressor candidate 2 Human genes 0.000 description 1
- 101710150339 Tumor suppressor candidate 2 Proteins 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 101710098624 Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 description 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
- 101710107570 Tyrosine-protein kinase Yes Proteins 0.000 description 1
- 102100029163 Ubiquitin carboxyl-terminal hydrolase 14 Human genes 0.000 description 1
- 101710091086 Ubiquitin carboxyl-terminal hydrolase 14 Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108091007916 Zinc finger transcription factors Proteins 0.000 description 1
- 102000038627 Zinc finger transcription factors Human genes 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- MXDSJQHFFDGFDK-CYBMUJFWSA-N [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2r)-2,4-dimethylpiperazine-1-carboxylate Chemical compound C=12C=C(OC(=O)N3[C@@H](CN(C)CC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F MXDSJQHFFDGFDK-CYBMUJFWSA-N 0.000 description 1
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 1
- USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 229950008805 abexinostat Drugs 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- QUHYUSAHBDACNG-UHFFFAOYSA-N acerogenin 3 Natural products C1=CC(O)=CC=C1CCCCC(=O)CCC1=CC=C(O)C=C1 QUHYUSAHBDACNG-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 244000193174 agave Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 101150045355 akt1 gene Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- YEQGPOVCXMZUBT-UHFFFAOYSA-N alteminostat Chemical compound C1CN(C)CCN1C(=O)N(CCCCCCC(=O)NO)C1=CC=C(C=2C=C3N(C)N=CC3=CC=2)C=C1 YEQGPOVCXMZUBT-UHFFFAOYSA-N 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- LJTSIMVOOOLKOL-FNRDIUJOSA-N antroquinonol Chemical compound COC1=C(OC)C(=O)[C@H](C)[C@@H](C\C=C(/C)CC\C=C(/C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-FNRDIUJOSA-N 0.000 description 1
- LJTSIMVOOOLKOL-KCZVDYSFSA-N antroquinonol Natural products COC1=C(OC)C(=O)[C@H](C)[C@@H](CC=C(/C)CCC=C(/C)CCC=C(C)C)[C@H]1O LJTSIMVOOOLKOL-KCZVDYSFSA-N 0.000 description 1
- 229950007511 apalutamide Drugs 0.000 description 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- IADUEWIQBXOCDZ-UHFFFAOYSA-N azetidine-2-carboxylic acid Chemical compound OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- HDRGJRSISASRAJ-WKPMUQCKSA-N bazlitoran Chemical compound CO[C@@H]1[C@H](O)[C@@H](COP(=O)(S)O[C@@H]2[C@@H](COP(=O)(S)O[C@H]3C[C@@H](O[C@@H]3COP(=O)(S)O[C@H]4C[C@@H](O[C@@H]4COP(=O)(S)O[C@H]5C[C@@H](O[C@@H]5COP(=O)(S)O[C@H]6C[C@@H](O[C@@H]6COP(=O)(S)O[C@H]7C[C@@H](O[C@@H]7COP(=O)(S)O[C@H]8C[C@@H](O[C@@H]8COP(=O)(S)O[C@H]9C[C@@H](O[C@@H]9COP(=O)(S)O[C@H]%10C[C@@H](O[C@@H]%10COP(=O)(S)O[C@@H]%11[C@@H](COP(=O)(S)O[C@@H]%12[C@@H](COP(=O)(S)O[C@H]%13C[C@@H](O[C@@H]%13COP(=O)(S)O[C@H]%14C[C@@H](O[C@@H]%14COP(=O)(S)O[C@H]%15C[C@@H](O[C@@H]%15COP(=O)(S)O[C@H]%16C[C@@H](O[C@@H]%16COP(=O)(S)O[C@H]%17C[C@@H](O[C@@H]%17COP(=O)(S)O[C@H]%18C[C@@H](O[C@@H]%18CO)N%19C=CC(=NC%19=O)N)N%20C=C(C)C(=O)NC%20=O)n%21cnc%22c(N)ncnc%21%22)N%23C=C(C)C(=O)NC%23=O)N%24C=CC(=NC%24=O)N)N%25C=C(C)C(=O)NC%25=O)O[C@H]([C@@H]%12OC)n%26cnc%27C(=O)NC(=Nc%26%27)N)O[C@H]([C@@H]%11OC)N%28C=CC(=O)NC%28=O)N%29C=C(C)C(=NC%29=O)N)n%30ccc%31C(=O)NC(=Nc%30%31)N)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)N%34C=CC(=NC%34=O)N)N%35C=C(C)C(=O)NC%35=O)N%36C=CC(=NC%36=O)N)N%37C=C(C)C(=O)NC%37=O)O[C@H]([C@@H]2OC)n%38cnc%39C(=O)NC(=Nc%38%39)N)O[C@H]1N%40C=CC(=O)NC%40=O HDRGJRSISASRAJ-WKPMUQCKSA-N 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229950002903 bivatuzumab Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- JCINBYQJBYJGDM-UHFFFAOYSA-N bms-911543 Chemical compound CCN1C(C(=O)N(C2CC2)C2CC2)=CC(C=2N(C)C=NC=22)=C1N=C2NC=1C=C(C)N(C)N=1 JCINBYQJBYJGDM-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- LLCSWKVOHICRDD-UHFFFAOYSA-N buta-1,3-diyne Chemical group C#CC#C LLCSWKVOHICRDD-UHFFFAOYSA-N 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229950006295 cerdulatinib Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229950000157 cipemastat Drugs 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229950009240 crenolanib Drugs 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108010011219 dUTP pyrophosphatase Proteins 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- URLVCROWVOSNPT-QTTMQESMSA-N desacetyluvaricin Natural products O=C1C(CCCCCCCCCCCC[C@@H](O)[C@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 URLVCROWVOSNPT-QTTMQESMSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 229960004497 dinutuximab Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 229950009964 drozitumab Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 229950004255 emibetuzumab Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- ZPLVYYNMRMBNGE-TWOQFEAHSA-N eponemycin Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)=C)C(=O)[C@@]1(CO)CO1 ZPLVYYNMRMBNGE-TWOQFEAHSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 229950004444 erdafitinib Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 108020004067 estrogen-related receptors Proteins 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229950009988 evofosfamide Drugs 0.000 description 1
- UGJWRPJDTDGERK-UHFFFAOYSA-N evofosfamide Chemical compound CN1C(COP(=O)(NCCBr)NCCBr)=CN=C1[N+]([O-])=O UGJWRPJDTDGERK-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- NHTKGYOMICWFQZ-BBOXMAMFSA-N fosgemcitabine palabenamide Chemical compound C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 NHTKGYOMICWFQZ-BBOXMAMFSA-N 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950002140 futuximab Drugs 0.000 description 1
- 229950003400 galeterone Drugs 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 229950010415 givinostat Drugs 0.000 description 1
- 229950000918 glembatumumab Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010025843 glutamine receptor Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 101150086609 groEL2 gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 150000002443 hydroxylamines Chemical group 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- OFNXOACBUMGOPC-UHFFFAOYSA-N hydroxystreptomycin Natural products CNC1C(O)C(O)C(CO)OC1OC1C(C=O)(O)C(CO)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O OFNXOACBUMGOPC-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 108010021518 integrin beta5 Proteins 0.000 description 1
- 108010021309 integrin beta6 Proteins 0.000 description 1
- 108010021315 integrin beta7 Proteins 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- OKPOKMCPHKVCPP-UHFFFAOYSA-N isoorientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(OC)=C(O)C=C3CCN2C)=C1 OKPOKMCPHKVCPP-UHFFFAOYSA-N 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950000822 lefitolimod Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- CJZRVARTODENJN-UHFFFAOYSA-N litenimod Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=S)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=S)OC(C(O1)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)CC1N1C=CC(N)=NC1=O CJZRVARTODENJN-UHFFFAOYSA-N 0.000 description 1
- 229950011554 litenimod Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 229950007627 motolimod Drugs 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 description 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- ZJFCBQXPTQSTCZ-UHFFFAOYSA-N n-[3-(2,4-difluorophenyl)-5-[5-(1-methylpyrazol-4-yl)benzimidazol-1-yl]phenyl]cyclopropanesulfonamide Chemical compound C1=NN(C)C=C1C1=CC=C(N(C=N2)C=3C=C(C=C(NS(=O)(=O)C4CC4)C=3)C=3C(=CC(F)=CC=3)F)C2=C1 ZJFCBQXPTQSTCZ-UHFFFAOYSA-N 0.000 description 1
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 description 1
- HUFOZJXAKZVRNJ-UHFFFAOYSA-N n-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N2CCN(CC2)C(C)=O)=CC=C1NC(N=1)=NC=C(C(F)(F)F)C=1NC1=CC=CC(NC(=O)C=C)=C1 HUFOZJXAKZVRNJ-UHFFFAOYSA-N 0.000 description 1
- RRTPWQXEERTRRK-UHFFFAOYSA-N n-[4-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)oxybutyl]octadecanamide Chemical compound C1=CC=CC2=C3N(OCCCCNC(=O)CCCCCCCCCCCCCCCCC)C(CCCC)=NC3=C(N)N=C21 RRTPWQXEERTRRK-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 1
- TWJZFXHSPBBPNI-UHFFFAOYSA-N n-hydroxy-2-[methyl-[[2-[6-(methylamino)pyridin-3-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide Chemical compound C1=NC(NC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 TWJZFXHSPBBPNI-UHFFFAOYSA-N 0.000 description 1
- 229950008353 narnatumab Drugs 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950004484 necuparanib Drugs 0.000 description 1
- 230000007837 negative regulation of B cell activation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 108010054353 p21(ras) farnesyl-protein transferase Proteins 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000022032 p53 binding proteins Human genes 0.000 description 1
- 108091012362 p53 binding proteins Proteins 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 229950005157 peficitinib Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 101150073897 plk1 gene Proteins 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 229950009876 poziotinib Drugs 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229950001626 quizartinib Drugs 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960005562 radium-223 Drugs 0.000 description 1
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 1
- 229950004043 radotinib Drugs 0.000 description 1
- DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- JTQHYPFKHZLTSH-UHFFFAOYSA-N reticulin Natural products COC1CC(OC2C(CO)OC(OC3C(O)CC(OC4C(C)OC(CC4OC)OC5CCC6(C)C7CCC8(C)C(CCC8(O)C7CC=C6C5)C(C)O)OC3C)C(O)C2OC)OC(C)C1O JTQHYPFKHZLTSH-UHFFFAOYSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229950006743 ricolinostat Drugs 0.000 description 1
- 229950006764 rigosertib Drugs 0.000 description 1
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 229950009855 rociletinib Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950000106 samalizumab Drugs 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- VXBAJLGYBMTJCY-NSCUHMNNSA-N sb1317 Chemical compound N=1C2=CC=NC=1NC(C=1)=CC=CC=1CN(C)C\C=C\CCOC1=CC=CC2=C1 VXBAJLGYBMTJCY-NSCUHMNNSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229950010613 selinexor Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229960000776 sodium tetradecyl sulfate Drugs 0.000 description 1
- 108010013351 sodium-iodide symporter Proteins 0.000 description 1
- 108091006284 sodium-phosphate co-transporters Proteins 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229950011267 solitomab Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 108020003486 sphingomyelin synthase Proteins 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- 229950001899 tasquinimod Drugs 0.000 description 1
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 229950005787 uprosertib Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 229950006959 vorsetuzumab Drugs 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229940095188 zydelig Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
本文提供6-胺基-9-[(3R)-1-(2-丁炔醯基)-3-吡咯啶基]-7-(4-苯氧基苯基)-7,9-二氫-8H-嘌呤-8-酮之形式、其組合物、其製備方法及其使用方法。
Description
本申請案概言之係關於用於治療疾病之治療劑及組合物,且更具體而言係關於布魯頓氏酪胺酸激酶(Bruton's Tyrosine Kinase,BTK)抑制劑。
BTK係激酶之Tec家族成員且參與B細胞中之信號轉導及肥胖細胞之活化。已將若干化合物鑑別為BTK抑制劑。實例揭示於以下中:美國專利第7,514,444號、第8,501,724號、第8,557,803號、第8,940,725號、第8,940,893號、第9,199,997及第9,371,325號;美國公開專利申請案第2014/0142099號;PCT公開案第WO 2008/121742號、第WO 2013/010380號、第WO 2013/010868號、第WO 2013/010869號、第WO 2015/002894及第WO 2015/048689號。將一些BTK抑制劑評估為(例如)自體免疫疾病及癌症之潛在治療劑。
需要研發抑制BTK以治療由BTK介導之疾病、病症或病況之治療劑。
在一態樣中,本文提供具有以下結構之化合物(I)之鹽及共晶體形式:
在一些態樣中,本文提供化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二 磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽。在某些態樣中,本文提供呈鹽或共晶體形式之化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽。
在另一態樣中,提供包含化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽及一或多種醫藥學上可接受之載劑或賦形劑的醫藥組合物。亦提供包含化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽之製品及單位劑型。亦提供包含本文所述化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽及使用說明書(例如,於BTK介導之病症、例如自體免疫疾病或癌症中之使用說明書)的套組。
在一種變化形式中,提供治療有需要之人類之BTK介導之病症之方法,其包含向人類投與化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽或其組合物(包括醫藥組合物)。在一些實施例中,BTK介導之病症係自體免疫疾病或癌症。
亦提供化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽或其組合物(包括醫藥組合物)之用途,其用於製造用於治療對BTK活性之抑制有反應之疾病(例如自體免疫疾病或癌症)的藥劑。
另外提供製造化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽之方法的此外,提供產生包含化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽之組合物的方法。
製造化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽之方法包含組合適宜酸及化合物(I)與適宜 溶劑或適宜溶劑混合物。適宜酸可包括但不限於硫酸、草酸、乙烷-1,2-二磺酸、萘-1,5-二磺酸、富馬酸及琥珀酸。適宜溶劑可包括但不限於甲醇、乙醇、水、乙酸異丙酯、乙酸乙酯、甲基第三丁基醚、正庚烷、乙腈、丙酮、2-甲基四氫呋喃、四氫呋喃、甲基異丁基酮、甲基乙基酮、二氯甲烷、2-丙醇、1-丙醇、1-丁醇及其任何混合物。亦提供藉由本文詳述之方法(例如製造方法)獲得之化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽。
可藉由參照以下說明結合附圖最佳地理解本揭示案。
圖1A-1D分別顯示化合物(I)半硫酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
圖2A-2D分別顯示化合物(I)草酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
圖3A-3D分別顯示化合物(I)半乙二磺酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
圖4A-4D分別顯示化合物(I)乙二磺酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
圖5A-5D分別顯示化合物(I)半萘二磺酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
圖6A-6D分別顯示化合物(I)富馬酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
圖7A-7D分別顯示化合物(I)琥珀酸鹽之X射線粉末繞射圖案(XRPD)圖案、差示掃描量熱法(DSC)溫度記錄圖、熱重分析(TGA)溫度記錄圖及動態氣相吸附(DVS)圖。
提供以下說明以使得熟習此項技術者能夠製得及使用各個實施例。具體化合物、方法、技術及應用之說明僅作為實例提供。彼等熟習此項技術者將容易地明瞭對本文所述實例之各種修改,且可在不背離各個實施例之精神及範疇的情況下將本文所述一般原理應用於其他實例及應用。因此,各個實施例並不意欲限於本文所述及顯示實例,而是被給與和申請專利範圍一致之範疇。
如本申請案中所使用,除非在使用其之上下文中另外指明,否則以下詞語及片語通常意欲具有如下文所述之含義。術語「約」包括且闡述值或參數本身。舉例而言,「約x」包括且闡述「x」本身。在某一實施例中,術語「約」在與量測結合使用或用於修飾值、單位、常數或值範圍時係指+/- 1-10%之變化。在一些實施例中,術語「約」在與量測結合使用或用於修飾值、單位、常數或值範圍時係指+/- 5%之變化。在一些實施例中,術語「約」在與量測結合使用或用於修飾值、單位、常數或值範圍時係指+/- 10%之變化。術語「之間」包括且闡述值或參數本身。舉例而言,「介於x與y之間」包括且闡述「x」及「y」本身。術語「及/或」包括替代之標的物以及組合之標的物。例如,「x及/或y」包括「x或y」以及「x及y」。
給定式之化合物意欲涵蓋本揭示案之化合物及該等化合物之鹽、酯、異構物、互變異構物、溶劑合物、同位素、水合物、形式(包括多形體、擬態多 晶型、晶體或共晶體形式)及前藥。另外,本揭示案之化合物可具有一或多個不對稱中心,且可以外消旋混合物、非外消旋混合物、非鏡像異構物之混合物或以個別鏡像異構物或非鏡像異構物形式產生。存在於給定式之任何給定化合物中之立體異構物的數量取決於所存在不對稱中心之數量(存在2n種可能的立體異構物,其中n係不對稱中心之數量)。個別立體異構物(包括個別鏡像異構物及非鏡像異構物)以及立體異構物之外消旋及非外消旋混合物涵蓋於本發明之範疇內,除非另外明確指示,否則其皆意欲由本說明書之結構來繪示。本揭示案之化合物包括可分離之旋轉異構物或阻轉異構物。
「異構物」係具有相同分子式之不同化合物。異構物包括立體異構物、鏡像異構物及非鏡像異構物。「立體異構物」係僅原子在空間中之排列方式不同之異構物。「鏡像異構物」係一對彼此為非重疊鏡像之立體異構物。鏡像異構物對之1:1混合物為「外消旋」混合物。若適當,術語「(±)」用於指示外消旋混合物。「非鏡像異構物」係具有至少兩個不對稱原子、但彼此不為鏡像之立體異構物。
根據Cahn Ingold Prelog R S系統來指定絕對立體化學。當化合物係純鏡像異構物時,每一手性碳之立體化學可指定為R或S。絕對構形未知之拆分化合物端視其在鈉D線波長下旋轉偏振光之平面之方向(右旋或左旋)指定為(+)或(-)。
「互變異構物」係由同一有機分子內之原子或官能基之遷移產生且導致其一或多個結構骨架、電子密度分佈及化學性質之變化的結構異構物。應理解,本文揭示之化合物包括互變異構形式,但未必明確顯示。在一個實例中,嘌呤可由以下互變異構物中之任一者表示:
因此,在提及嘌呤互變異構物種之任一者時包括其他互變異構形式。
若所繪示結構與給與該結構之名稱之間存在差異,則以所繪示結構為準。此外,若結構或結構之一部分的立體化學未以(例如)粗體、楔形線或虛線表示出來,則應將該結構或該結構之一部分理解為涵蓋其所有立體異構物。
術語「溶劑合物」係指藉由組合如本文揭示之任何式之化合物與溶劑所形成的複合物。術語「水合物」係指藉由組合本文揭示之任何式之化合物與水所形成的複合物。
本文給出之任一式或結構亦意欲表示化合物之未標記形式以及經同位素標記形式。經同位素標記之化合物具有由本文所給出式繪示之結構,只是一或多個原子由具有所選原子質量或質量數的原子置換。可納入本揭示案之化合物中之同位素的實例包括氫、碳、氮、氧、磷、氟及氯之同位素,例如但不限於2H(氘,D)、3H(氚)、11C、13C、14C、15N、18F、31P、32P、35S、36Cl及125I。本揭示案之各種經同位素標記之化合物,例如其中納入諸如例如3H、13C及14C等放射性同位素之彼等。此等經同位素標記之化合物可用於代謝研究、反應動力學研究、檢測或成像技術(例如正電子發射斷層攝影(PET)或單光子發射電腦斷層攝影(SPECT),包括藥物或受質組織分佈分析)或患者之放射性治療。
本揭示案亦包括本文揭示之任一式之化合物,其中附接至碳原子之1至「n」個氫由氘置換,其中n係分子中氫之數量。該等化合物在投與哺乳動物時展現增加之代謝抗性且因此可用於延長式(I)-(III)化合物之半衰期。參見(例如)Foster,「Deuterium Isotope Effects in Studies of Drug Metabolism」,Trends Pharmacal.Sci.5(12):524-527(1984)。該等化合物係藉由業內熟知之方式(例如藉由採用一或多個氫原子經氘置換之起始材料)來合成。
本揭示案之經氘標記或取代之治療化合物具有改良之與分佈、代謝及排泄(ADME)相關之DMPK(藥物代謝及藥物動力學)性質。用較重同位素(例 如氘)進行取代因更強代謝穩定性可提供某些治療優點,例如延長之活體內半衰期或降低之劑量需求。18F標記之化合物可用於PET或SPECT研究。經同位素標記之本揭示案之化合物及其前藥通常可藉由實施在反應圖中或在下文所述實例及製備中所揭示之程序藉由用易於獲得之經同位素標記之試劑取代未經同位素標記之試劑來製備。此外,用較重同位素、尤其氘(亦即,2H或D)進行取代因更強代謝穩定性可提供某些治療優點,例如延長之活體內半衰期或劑量需求降低或治療指數改良。應瞭解,在此上下文中氘被視為本文揭示之任一式之化合物之取代基。
該較重同位素(具體而言氘)之濃度可由同位素富集因子定義。在本揭示案之化合物中,未明確命名為同位素之任何原子意指代表該原子之任何穩定同位素。除非另外陳述,否則在位置明確命名為「H」或「氫」時,該位置應理解為在其天然豐度同位素組合物處具有氫。因此,在本揭示案之化合物中,明確命名為氘(D)之任何原子意欲代表氘。
在許多情形下,本揭示案之化合物藉助胺基及/或羧基或與其類似之基團之存在能夠形成酸及/或鹼式鹽。鹼或酸加成鹽可自無機及有機鹼來製備。
在一些實施例中,鹽係「醫藥學上可接受之鹽」。給定化合物之醫藥學上可接受之鹽係指保留給定化合物之生物有效性及性質且在生物或其他方面合意之鹽。參見:P.Heinrich Stahl及Camille G.Wermuth(編輯)Pharmaceutical Salts:Properties,Selection,and Use(International Union of Pure and Applied Chemistry),Wiley-VCH;第2修訂版(2011年5月16日)。
本文所述化合物可以化學結構或名稱形式提供。舉例而言,化合物(I)可使用ChemBioDraw Ultra 10.0命名且應理解為可使用其他名稱來鑑別相同結構之化合物。其他化合物或基團可利用共用名稱或系統性或非系統性名稱來命名。該等化合物亦可使用化學領域中公認之其他命名系統及符號(包括例如化 學文摘服務社(Chemical Abstract Service,CAS)及國際純化學及應用化學聯合會(International Union of Pure and Applied Chemistry,IUPAC))來命名。
本申請案提供抑制BTK活性、適用作BTK抑制劑之化合物。在一態樣中,BTK抑制劑係具有以下結構之化合物(I)之鹽或形式:
化合物(I)亦可表示為6-胺基-9-[(3R)-1-(2-丁炔醯基)-3-吡咯啶基]-7-(4-苯氧基苯基)-7,9-二氫-8H-嘌呤-8-酮。
在另一態樣中,BTK抑制劑係化合物(I)之鹽或共晶體形式。在某一實施例中,BTK抑制劑係化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽。化合物(I)之半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽及琥珀酸鹽可以任何形式、包括鹽或共晶體形式提出。該等鹽或共晶體形式可由各種固態分析數據(包括例如X射線粉末繞射圖案(XRPD)、差示掃描量熱法(DSC)、熱重分析(TGA)及單晶X射線結晶學)表徵。熟習此項技術者應識別可用於生成該等表徵數據之各種技術或方法。除非另外陳述,否則本文提供之XRPD圖案係於室溫下藉由粉末X射線繞射儀生成。
化合物(I)之結晶鹽或共晶體形式可提供生物利用度及穩定性之優點,其適用作醫藥組合物中之活性成分。美國專利第8,557,803中揭示之6-胺基-9-[(3R)-1-(2-丁炔醯基)-3-吡咯啶基]-7-(4-苯氧基苯基)-7,9-二氫-8H-嘌呤-8-酮係BTK抑制劑之實例。BTK抑制劑之鹽揭示於(例如)美國專利第9,199,997號及第 9,371,325號中。該等參照文獻中之每一者之全文以引用方式併入本文中。與第9,199,997號及第9,371,325號中揭示之鹽之溶解度相比,化合物(I)半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽之鹽或共晶體形式可具有類似或增強之溶解度。在一些實施例中,化合物(I)之鹽或共晶體形式、本申請案之化合物、本文所述化合物、本申請案之BTK抑制劑、此處所述BTK抑制劑或其變化形式之術語係指呈鹽或共晶體形式之化合物(I)半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽。醫藥原料藥或活性成分之晶體結構之變化可影響醫藥產品或活性成分之溶解速率(其可影響生物利用度)、可製造性(例如,易於操作、能夠一致地製備已知強度之劑量)及穩定性(例如,熱穩定性、儲放壽命)。該等變化可影響呈不同劑量或遞送形式(例如固體經口劑型,包括錠劑及膠囊)之醫藥組合物之製備或調配。與其他形式(例如非結晶或非晶型)相比,結晶型可提供期望或適宜吸濕性、粒徑控制、溶解速率、溶解度、純度、物理及化學穩定性、可製造性、產率及/或過程控制。因此,化合物(I)之結晶鹽或共晶體形式可提供如下優點:改良活性劑之製造過程或化合物或活性成分之藥物產品形式之穩定性或可儲存性,或具有作為活性劑之適宜生物利用度及/或穩定性。
已發現使用某些酸可產生不同固體形式之化合物(I),包括半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽及琥珀酸鹽形式,其可展現本文所述之一或多種有利之特徵,包括但不限於生物利用度及穩定性。本文所述形式之製備及表徵之過程。術語「實質上如……中所示」在提及(例如)XRPD圖案、DSC溫度記錄圖、TGA溫度記錄圖或DVS圖時包括不必與本文繪示之彼等相同、但在由熟習此項技術者考慮時在實驗誤差或偏差之限制內的圖案、溫度記錄圖或圖。
在一態樣中,提供化合物(I)半硫酸鹽,其中結晶型展現實質上如圖1A中所示之XRPD圖案。化合物(I)半硫酸鹽展現實質上如圖1B中所示之差示掃描量熱法(DSC)溫度記錄圖。化合物(I)半硫酸鹽展現實質上如圖1C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)半硫酸鹽展現實質上如圖1D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)半硫酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質上如圖1A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包括針對化合物(I)半硫酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)半硫酸鹽具有包含6.6、18.6及23.7之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)半硫酸鹽具有包含6.6、7.1、13.7、18.6及23.7之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)半硫酸鹽具有包含自約25℃至約150℃約0.6%之重量損失之熱重分析溫度記錄圖。在某些實施例中,化合物(I)半硫酸鹽具有包含約192℃下之吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)半硫酸鹽具有包含於約25℃下自約10%至約90% RH約1.2%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)半硫酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖1A中所示之XRPD圖案;(b)實質上如圖1B中所示之DSC溫度記錄圖。
在一態樣中,提供化合物(I)草酸鹽,其中結晶型展現實質上如圖2A中所示之XRPD圖案。化合物(I)草酸鹽展現實質上如圖2B中所示之差示掃描量 熱法(DSC)溫度記錄圖。化合物(I)草酸鹽展現實質上如圖2C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)草酸鹽展現實質上如圖2D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)草酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質上如圖2A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包括針對化合物(I)草酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)草酸鹽具有包含7.2、18.2及23.3之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)草酸鹽具有包含7.2、13.8、18.2、20.2及23.3之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)草酸鹽具有包含自約25℃至約100℃約0.6%之重量損失之熱重分析溫度記錄圖。在一個實施例中,化合物(I)草酸鹽之溫度記錄圖進一步包含自約100℃至約200℃約11%之重量損失。在某些實施例中,化合物(I)草酸鹽具有包含約171℃下之吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)草酸鹽具有包含於約25℃下自約10%至約90% RH約0.5%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)草酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖2A中所示之XRPD圖案;(b)實質上如圖2B中所示之DSC溫度記錄圖。
在一態樣中,提供化合物(I)半乙二磺酸鹽,其中結晶型展現實質上如圖3A中所示之XRPD圖案。化合物(I)半乙二磺酸鹽展現實質上如圖3B中所示之差示掃描量熱法(DSC)溫度記錄圖。化合物(I)半乙二磺酸鹽展現實質上如圖 3C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)半乙二磺酸鹽展現實質上如圖3D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)半乙二磺酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質上如圖3A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包括針對化合物(I)半乙二磺酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)半乙二磺酸鹽具有包含5.9、11.8及17.6之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)半乙二磺酸鹽具有包含5.9、11.8、17.6、21.2及23.6之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)半乙二磺酸鹽具有包含自約25℃至約100℃約3.3%之重量損失之熱重分析溫度記錄圖。在某些實施例中,化合物(I)半乙二磺酸鹽具有包含約165℃下之吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)半乙二磺酸鹽具有包含於約25℃下自約10%至約90% RH約3%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)半乙二磺酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖3A中所示之XRPD圖案;(b)實質上如圖3B中所示之DSC溫度記錄圖。
在一態樣中,提供化合物(I)乙二磺酸鹽,其中結晶型展現實質上如圖4A中所示之XRPD圖案。化合物(I)乙二磺酸鹽展現實質上如圖4B中所示之差示掃描量熱法(DSC)溫度記錄圖。化合物(I)乙二磺酸鹽展現實質上如圖4C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)乙二磺酸鹽展現實質上如圖4D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)乙二磺酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質上如圖4A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包括針對化合物(I)乙二磺酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)乙二磺酸鹽具有包含5.7、16.6及24.2之°2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)乙二磺酸鹽具有包含5.7、11.1、16.6、22.2及24.2之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)乙二磺酸鹽具有包含自約25℃至約100℃約4.0%之重量損失之熱重分析溫度記錄圖。在某些實施例中,化合物(I)乙二磺酸鹽具有包含約154℃下之吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)乙二磺酸鹽具有包含於約25℃下自約10%至約90% RH約22%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)乙二磺酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖4A中所示之XRPD圖案;(b)實質上如圖4B中所示之DSC溫度記錄圖。
在一態樣中,提供化合物(I)半萘二磺酸鹽,其中結晶型展現實質上如圖5A中所示之XRPD圖案。化合物(I)半萘二磺酸鹽展現實質上如圖5B中所示之差示掃描量熱法(DSC)溫度記錄圖。化合物(I)半萘二磺酸鹽展現實質上如圖5C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)半萘二磺酸鹽展現實質上如圖5D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)半萘二磺酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質 上如圖5A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包括針對化合物(I)半萘二磺酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)半萘二磺酸鹽具有包含15.5、16.5及23.8之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)半萘二磺酸鹽具有包含5.6、15.5、16.5、20.3及23.8之° 2θ反射(+/-0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)半萘二磺酸鹽具有包含自約25℃至約125℃約1.5%之重量損失之熱重分析溫度記錄圖。在某些實施例中,化合物(I)半萘二磺酸鹽具有包含約180℃下之吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)半萘二磺酸鹽具有包含於約25℃下自約10%至約90% RH約6.5%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)半萘二磺酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖5A中所示之XRPD圖案;(b)實質上如圖5B中所示之DSC溫度記錄圖。
在一態樣中,提供化合物(I)富馬酸鹽,其中結晶型展現實質上如圖6A中所示之XRPD圖案。化合物(I)富馬酸鹽展現實質上如圖6B中所示之差示掃描量熱法(DSC)溫度記錄圖。化合物(I)富馬酸鹽展現實質上如圖6C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)富馬酸鹽展現實質上如圖6D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)富馬酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質上如圖6A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包 括針對化合物(I)富馬酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)富馬酸鹽具有包含13.0、16.6及19.9之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)富馬酸鹽具有包含8.3、13.0、16.6、19.0及19.9之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)富馬酸鹽具有包含自約25℃至約100℃約0.04%之重量損失之熱重分析溫度記錄圖。在某些實施例中,化合物(I)富馬酸鹽具有包含約158℃下之吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)富馬酸鹽具有包含於約25℃下自約10%至約90% RH約0.1%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)富馬酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖6A中所示之XRPD圖案;(b)實質上如圖6B中所示之DSC溫度記錄圖。
在一態樣中,提供化合物(I)琥珀酸鹽,其中結晶型展現實質上如圖7A中所示之XRPD圖案。化合物(I)琥珀酸鹽展現實質上如圖7B中所示之差示掃描量熱法(DSC)溫度記錄圖。化合物(I)琥珀酸鹽展現實質上如圖7C中所示之熱重分析(TGA)溫度記錄圖。化合物(I)琥珀酸鹽展現實質上如圖7D中所示之動態氣相吸附(DVS)圖。
在一些實施例中,化合物(I)琥珀酸鹽具有展示具有最大強度之至少兩個、至少三個、至少四個或至少五個° 2θ反射的XRPD圖案,作為實質上如圖7A中所示之XRPD圖案。應理解,相對強度可根據多個因素(包括樣品製備、安裝及用於獲得譜之儀器及分析程序及設置)變化。因此,本文列舉之峰歸屬(包括針對化合物(I)琥珀酸鹽)意欲涵蓋+/- 0.2° 2θ之變化。
在某些實施例中,化合物(I)琥珀酸鹽具有包含13.2、16.5及18.0之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。在一個實施例中,化合物(I)琥珀酸鹽具有包含8.2、13.2、16.5、18.0及18.6之° 2θ反射(+/- 0.2° 2θ)之XRPD圖案。
在某些實施例中,化合物(I)琥珀酸鹽具有包含自約25℃至約125℃約0.2%之重量損失之熱重分析溫度記錄圖。在某些實施例中,化合物(I)琥珀酸鹽具有包含約142℃及約160℃下之兩個吸熱之差示掃描量熱曲線。在某些實施例中,化合物(I)琥珀酸鹽具有包含於約25℃下自約10%至約90% RH約0.2%之水攝取的動態氣相吸附等溫線。在一些實施例中,化合物(I)琥珀酸鹽具有以下性質中之至少一者或二者:(a)實質上如圖7A中所示之XRPD圖案;(b)實質上如圖7B中所示之DSC溫度記錄圖。
本發明化合物具有BTK抑制活性且因此可用作用於預防及/或治療BTK有關之疾病(亦即,B細胞及/或肥胖細胞參與之疾病,例如過敏性病、自體免疫疾病、發炎性疾病、血栓栓塞性疾病、癌症及移植抗宿主疾病)之試劑。本發明化合物亦實踐對B細胞活化之選擇性抑制作用且因此有效用作B細胞活化之抑制劑。
合成化合物(I)之一種方法已先前闡述於美國專利第8,557,803號中。此參考文獻之全文且具體而言關於化合物(I)之合成以引用方式併入本文中。本文所述化合物(I)之鹽或共晶體形式可自化合物(I)製備。舉例而言,在一態樣中,提供產生包含本文所述化合物(I)之鹽或共晶體形式之組合物的方法,其中該方法包含組合化合物(I)與適宜酸及適宜溶劑或適宜溶劑之混合物以產生包含本文所述化合物(I)之鹽或共晶體形式之組合物。
適於鹽或共晶體形成之酸可包括但不限於(例如)硫酸、草酸、乙烷-1,2-二磺酸、萘-1,5-二磺酸、富馬酸及琥珀酸。適於鹽或共晶體形成之溶劑可包 括但不限於(例如)甲醇、乙醇、水、乙酸異丙酯、乙酸乙酯、甲基第三丁基醚、正庚烷、乙腈、丙酮、2-甲基四氫呋喃、四氫呋喃、甲基異丁基酮、甲基乙基酮、二氯甲烷、2-丙醇、1-丙醇、1-丁醇及其任何混合物。在另一態樣中,亦提供根據本文所述方法中之任一者產生之本文所述化合物(I)的鹽或共晶體形式。
在一個實施例中,提供產生包含化合物(I)半硫酸鹽之組合物之方法,其中該方法包含(i)組合化合物(I)與硫酸及適宜溶劑以獲得混合物;(ii)將步驟(i)中獲得之混合物加熱至約70℃;(iii)將步驟(ii)中獲得之混合物冷卻至約0℃;及(iv)收集步驟(iii)中獲得之固體材料以獲得化合物(I)半硫酸鹽。
在另一實施例中,提供產生包含化合物(I)草酸鹽之組合物之方法,其中該方法包含(i)於約21℃下組合化合物(I)與草酸及適宜溶劑以獲得混合物;(ii)收集步驟(i)中獲得之固體材料以獲得化合物(I)草酸鹽。
在另一實施例中,提供產生包含化合物(I)半乙二磺酸鹽之組合物之方法,其中該方法包含(i)於約21℃下組合化合物(I)與乙烷-1,2-二磺酸二水合物及適宜溶劑以獲得混合物;(ii)收集步驟(i)中獲得之固體材料以獲得化合物(I)半乙二磺酸鹽。
在另一實施例中,提供產生包含化合物(I)乙二磺酸鹽之組合物之方法,其中該方法包含(i)於約21℃下組合化合物(I)與乙烷-1,2-二磺酸二水合物及適宜溶劑以獲得混合物;(ii)收集步驟(i)中獲得之固體材料以獲得化合物(I)乙二磺酸鹽。
在另一實施例中,提供產生包含化合物(I)半萘二磺酸鹽之組合物之方法,其中該方法包含(i)組合化合物(I)與萘-1,5-二磺酸及適宜溶劑以獲得混合物;(ii)將步驟(i)中獲得之混合物加熱至約50℃;(iii)將步驟ii)中獲得之混合物冷卻至約20℃;及(iv)收集步驟(iii)中獲得之固體材料以獲得化合物(I)半萘二磺酸鹽。
在另一實施例中,提供產生包含化合物(I)富馬酸鹽之組合物之方法,其中該方法包含(i)組合化合物(I)與富馬酸及適宜溶劑;(ii)將步驟(i)中獲得之混合物加熱至約50℃;(iii)將步驟(ii)中獲得之混合物冷卻至約20℃;及(iv)收集步驟(iii)中獲得之固體材料以獲得化合物(I)富馬酸鹽。
在另一實施例中,提供產生包含化合物(I)琥珀酸鹽之組合物之方法,其中該方法包含(i)組合化合物(I)與琥珀酸及適宜溶劑;(ii)將步驟(i)中獲得之混合物加熱至約50℃;(iii)將步驟(ii)中獲得之混合物冷卻至約20℃;及(iv)收集步驟(iii)中獲得之固體材料以獲得化合物(I)琥珀酸鹽。
在用以產生本文所述化合物(I)之鹽或共晶體形式之上述方法之一些實施例中,該方法進一步包含自所得組合物分離鹽或共晶體。可採用業內已知用以自組合物分離鹽或共晶體形式之任何適宜技術或方法。舉例而言,可藉由已知方法(例如過濾及/或蒸發)移除上述方法中所用之溶劑或溶劑混合物以分離自組合物產生之鹽或共晶體。
在一些實施例中,本文所述組合物可包含實質上純的本文所述化合物(I)之鹽或共晶體形式或可實質上不含其他多形體及/或雜質。在一些實施例中,關於本文所述化合物(I)半硫酸鹽、草酸鹽、半乙二磺酸鹽、乙二磺酸鹽、半萘二磺酸鹽、富馬酸鹽或琥珀酸鹽之鹽或共晶體形式之術語「實質上純」或「實質上不含」意指包含本文所述化合物(I)之鹽或共晶體形式的組合物含有小於95重量%、小於90重量%、小於80重量%、小於70重量%、小於65重量%、小於60重量%、小於55重量%、小於50重量%、小於40重量%、小於30重量%、小於20重量%、小於15重量%、小於10重量%、小於重量5%或小於重量1%之其他物質,包括其他多晶型及/或雜質。在某些實施例中,「實質上純的」或「實質上不含」係指物質不含其他物質,包括其他多晶型及/或雜質。雜質可(例 如)包括來自化學反應之副產物或剩下之試劑、污染物、降解產物、其他多晶型、水及溶劑。
在一些實施例中,組合物包含本文所述化合物(I)之鹽或共晶體之多晶型。在某些實施例中,提供包含本文所述化合物(I)之鹽或共晶體形式之組合物,其中組合物內之化合物(I)之鹽或共晶體之多晶型係實質上純的多晶型。在包含本文所述化合物(I)之鹽或共晶體之多晶型的組合物之其他實施例中,至少約50%、至少約60%、至少約70%、至少約80%、至少約85%、至少約90%、至少約95%、至少約96%、至少約97%、至少約98%或至少約99%之組合物中之化合物(I)之鹽或共晶體呈本文所述化合物(I)之鹽或共晶體之多晶型。
在包含本文所述化合物(I)之鹽或共晶體之多晶型的組合物之其他實施例中,小於約50%、小於約40%、小於約30%、小於約20%、小於約10%、小於約5%、小於約4%、小於約3%、小於約2%或小於約1%之存於組合物中之化合物(I)之鹽或共晶體係化合物(I)之鹽或共晶體之其他多晶型及/或雜質。在包含本文所述化合物(I)之鹽或共晶體形式之組合物的其他實施例中,相對於存在之本文所述化合物(I)之鹽或共晶體形式之質量,雜質佔總質量之小於約5%、小於約4%、小於約3%、小於約2%或小於約1%。雜質可(例如)包括自合成本文所述化合物(I)之鹽或共晶體形式產生之副產物、污染物、降解產物、其他多晶型、水及溶劑。
在其他實施例中,包含本文所述化合物(I)之鹽或共晶體形式之組合物具有小於約5重量%、小於約4重量%、小於約3重量%、小於約2重量%或小於約1重量%之化合物(I)之鹽或共晶體之非晶形或非結晶型。在其他實施例中,包含本文所述化合物(I)之鹽或共晶體形式之組合物具有小於約5重量%、小於約4重量%、小於約3重量%、小於約2重量%或小於約1重量%之化合物(I)(亦即,呈其游離形式)。
本文所述化合物(I)之鹽或共晶體形式可作為淨化學物質投與,但通常且較佳投與呈醫藥組合物或調配物形式之化合物。因此,提供醫藥組合物,其包含本文所述化合物(I)之鹽或共晶體形式及一或多種醫藥學上可接受之載劑、賦形劑或其他成分(包括惰性固體稀釋劑及填充劑、稀釋劑(包括無菌水溶液及各種有機溶劑)、滲透增強劑、增溶劑及佐劑)。組合物可包括呈單獨活性劑形式或與其他試劑(例如與一或多種醫藥學上可接受之載劑、賦形劑或其他成分混合之寡核苷酸或多核苷酸、寡肽或多肽、藥物或激素)組合之本文所述化合物(I)之鹽或共晶體形式。只要載劑、賦形劑及其他成分與調配物之其他成分相容且對其接受者無害,則可認為其係醫藥學上可接受的。
本文提供包含本文所述化合物(I)之鹽或共晶體形式及醫藥學上可接受之載劑或賦形劑的醫藥組合物。用於調配及投與醫藥組合物之技術可參見Remington's Pharmaceutical Sciences,第18版,Mack Publishing公司,Easton,Pa.,1990。本文所述醫藥組合物可使用任何習用方法(例如混合、溶解、製粒、製糖衣、磨細、乳化、囊封、截留、熔紡、噴霧乾燥或凍乾過程)製造。可由熟習此項技術者根據投與途徑及期望劑量測定最佳醫藥調配物。該等調配物可影響所投與試劑之物理狀態、穩定性、活體內釋放速率及活體內清除速率。端視所治療之病況而定,該等醫藥組合物可經調配且全身性或局部投與。
醫藥組合物可經調配以含有適宜醫藥學上可接受之載劑,且視情況可包含賦形劑及有利於將本文所述化合物(I)之鹽或共晶體形式處理成可在醫藥學上使用之製劑之輔助劑。投與方式通常決定載劑之性質。舉例而言,非經腸投與之調配物可包括呈水溶形式之活性化合物之水溶液。適於非經腸投與之載劑可選自鹽水、緩衝鹽水、右旋糖、水及其他生理上相容之溶液。非經腸投與之較佳載劑係生理上相容之緩衝液,例如漢克氏溶液(Hanks's solution)、林格氏溶液(Ringer's solution)或生理緩衝鹽水。對於組織或細胞投與,在調配物中使用 適於欲滲透之特定障壁之滲透劑。該等滲透劑通常為業內已知。對於包括蛋白質之製劑,調配物可包括穩定材料,例如多元醇(例如,蔗糖)及/或表面活性劑(例如,非離子型表面活性劑)及諸如此類。
或者,非經腸使用之調配物可包括製備為適當油性注射懸浮液之本文所述化合物(I)之鹽或共晶體形式的分散液或懸浮液。適宜親脂性溶劑或媒劑包括脂肪油(例如芝麻油)或合成脂肪酸酯(例如油酸乙酯或三酸甘油酯)或脂質體。水性注射懸浮液可含有增加懸浮液之黏度之物質,例如羧甲基纖維素鈉、山梨醇、葡聚糖及其混合物。視情況,懸浮液亦可含有適宜穩定劑或增加化合物之溶解度之試劑以容許製備高度濃縮之溶液。提供活性劑之pH敏感性溶解及/或持續釋放之水性聚合物亦可用作包衣或基質結構,例如甲基丙烯酸聚合物,例如自Rohm America公司(Piscataway,N.J.)購得之EUDRAGITTM系列。亦可使用乳液(例如水包油及油包水分散液),視情況由乳化劑或分散劑(表面活性材料;表面活性劑)穩定。懸浮液亦可含有懸浮劑,例如乙氧基化異硬脂醇、聚氧乙烯山梨糖醇及山梨醇酐酯、微晶纖維素、偏氫氧化鋁、膨潤土、瓊脂-瓊脂、黃蓍膠及其混合物。
含有本文所述化合物(I)之鹽或共晶體形式之脂質體亦可用於非經腸投與。脂質體通常係衍生自磷脂或其他脂質物質。呈脂質體形式之組合物亦可含有其他成分,例如穩定劑、防腐劑、賦形劑及諸如此類。較佳脂質包括磷脂及磷脂醯基膽鹼(卵磷脂),二者係天然及合成的。形成脂質體之方法為業內已知。參見(例如)Prescott(編輯),Methods in Cell Biology,第XIV卷,第33頁,Academic Press,New York(1976)。
在一些實施例中,使用業內熟知之醫藥學上可接受之載劑、賦形劑或其他成分調配本文所述化合物(I)之鹽或共晶體形式或本文揭示之其組合物用於經口投與。經調配用於經口投與之製劑可呈錠劑、丸劑、膠囊、扁囊劑、糖 衣錠、菱形錠劑、液體、凝膠、糖漿、漿液、酏劑、懸浮液或粉末形式。為了闡釋,用於經口使用之醫藥製劑可藉由組合活性化合物與固體賦形劑、視情況研磨所得混合物及在添加適宜輔助劑(若期望)後處理混合物以獲得錠劑或糖衣錠核來獲得。經口調配物可採用類似與針對非經腸使用所述之彼等類似之液體載劑,例如緩衝水溶液、懸浮液及諸如此類。
較佳之經口調配物包括錠劑、糖衣錠及明膠膠囊。該等製劑可含有一或多種賦形劑,其包括但不限於:a)稀釋劑,例如微晶纖維素及糖,包括乳糖、右旋糖、蔗糖、甘露醇或山梨醇;b)黏合劑,例如澱粉羥乙酸鈉、交聯羧甲基纖維素鈉、矽酸鋁鎂、來自玉米、小麥、稻穀、馬鈴薯等之澱粉;c)纖維素材料(例如甲基纖維素、羥丙基甲基纖維素及羧甲基纖維素鈉)、聚乙烯基吡咯啶酮、樹膠(例如阿拉伯膠及黃蓍膠)及蛋白質(例如明膠及膠原);d)崩解或增溶劑,例如交聯聚乙烯吡咯啶酮、澱粉、瓊脂、海藻酸或其鹽(例如海藻酸鈉)或泡騰劑組合物;e)潤滑劑,例如二氧化矽、滑石、硬脂酸或其鎂或鈣鹽及聚乙二醇;f)矯味劑及甜味劑;g)例如用於鑑別產物或表徵活性化合物之量(劑量)之著色劑或顏料;及h)其他成分,例如防腐劑、穩定劑、溶脹劑、乳化劑、促溶劑、用於調節滲透壓之鹽及緩衝液。
舉例而言,提供包含本文所述化合物(I)之鹽或共晶體形式及一或多種醫藥學上可接受之載劑或賦形劑的錠劑。在一個實施例中,錠劑實質上不含化合物(I)之非晶形或非結晶型。在另一實施例中,錠劑實質上不含游離(鹼)化合物(I)。
明膠膠囊包括由明膠製得之推入配合膠囊以及由明膠及諸如甘油或 山梨醇等包衣製得之軟的密封膠囊。推入配合膠囊可含有與填充劑、黏合劑、潤滑劑及/或穩定劑等混合之活性成分。在軟膠囊中,活性化合物可溶解或懸浮於具有或無穩定劑之適宜流體(例如脂肪油、液體石蠟或液體聚乙二醇)中。糖衣錠核可提供有適宜包衣,例如濃縮之糖溶液,其亦可含有阿拉伯膠、滑石、聚乙烯吡咯啶酮、卡波姆凝膠、聚乙二醇及/或二氧化鈦、漆溶液及適宜有機溶劑或溶劑混合物。
組合物較佳調配成單位劑型。術語「單位劑型」係指適於作為單位劑量供人類個體及其他哺乳動物使用之物理離散單位,每一單位含有經計算以產生期望治療效果之預定量的活性物質以及適宜醫藥賦形劑(例如,錠劑、膠囊或安瓿)。本文所述化合物(I)之鹽或共晶體形式在寬劑量範圍內有效且通常以醫藥有效量投與。然而,應理解,本文所述化合物(I)之鹽或共晶體形式之實際投與量通常將由醫師根據包括以下在內之相關情況確定:欲治療之病況、所選投與途徑、接受該治療之個體之年齡、體重及反應、個體症狀之嚴重程度及諸如此類。
本文所述錠劑或丸劑可經塗佈或以其他方式複合以提供得到延長作用之優點之劑型,或保護免於胃之酸條件影響。例如,錠劑或丸劑可包含內部劑量要素及外部劑量要素,後者為前者上之包膜形式。該兩種要素可由腸溶性層分開,該腸溶性層用於抵抗胃內之分解作用並允許內部要素完整地進入十二指腸或延遲釋放。該等腸溶性層或包衣可使用多種材料,該等材料包括多種多晶酸及多晶酸與諸如蟲膠、十六烷醇及乙酸纖維素等材料之混合物。
舉例而言,提供包含本文所述化合物(I)之鹽或共晶體形式的單位劑量。在某些變化形式中,用於人類個體之本文所述化合物(I)之鹽或共晶體形式之實例性單位劑量值可介於約0.01mg至約1000mg之間,或介於約1mg至約200mg之間,或介於約10mg至約200mg之間,或介於約20mg至約160mg 之間,或介於約10mg至約100mg之間,或介於約50mg至約175mg之間,或介於約20mg至約150mg之間,或介於約75mg至約100mg之間,或介於約100mg至約200mg之間。可投與有需要之人類之本文所述化合物(I)之鹽或共晶體形式之個別劑量包括1mg、5mg、10mg、20mg、30mg、40mg、50mg、60mg、70mg、75mg、80mg、90mg、100mg、110mg、120mg、130mg、140mg、150mg、160mg、170mg、175mg及200mg之個別劑量。本文所述化合物(I)之鹽或共晶體形式之劑量可如由醫學專業人士所測定投與且可每日一次投與或可每日兩次、每日三次或每日四次遞送。在一個實施例中,本文所述化合物(I)之鹽或共晶體形式係以20mg、40mg、80mg或150mg之劑量每天一次經口投與有需要之個體。在一些實施例中,本文所述化合物(I)之鹽或共晶體形式係以20mg、40mg或75mg之劑量每天兩次經口投與個體。在額外實施例中,本文所述BTK抑制劑之治療有效量係約1mg至約200mg之劑量。在另一實施例中,本文所述BTK抑制劑係以約10mg至約200mg之劑量投與。在另一實施例中,人類中之BTK係以約20mg至約160mg之劑量投與。在另一實施例中,BTK抑制劑係以如下劑量投與人類:a)約10mg至約100mg,b)約50mg至約175mg,c)約20mg至約150mg,d)約75mg至約100mg,及e)約100mg至約200mg。可投與有需要之人類之BTK抑制劑之個別劑量包括1mg、5mg、10mg、20mg、30mg、40mg、50mg、60mg、70mg、75mg、80mg、901mg、100mg、110mg、120mg、130mg、140mg、150mg、160mg、170mg、175mg及200mg之個別劑量。BTK抑制劑之劑量可如由醫學專業人士所測定投與且可每日一次投與或可每日兩次、每日三次或每日四次遞送。在一個實施例中,本申請案之方法包含以10mg、20mg、40mg、80mg、150mg或200mg之劑量每日投與式(I)-(III)之BTK抑制劑或其組合物。在另一實施例中,本申請案之方法包含以20mg、40mg、80mg或150mg之劑量每日投與式(I)-(III)之BTK抑 制劑或其組合物。
包括本文所述化合物(I)之鹽或共晶體形式之醫藥組合物藉由任何習用方法、包括非經腸及腸內技術投與個體。非經腸投與方式包括藉由除經胃腸道以外之途徑(例如靜脈內、動脈內、腹膜內、髓內、肌內、關節內、鞘內及室內注射)投與組合物之彼等方式。腸內投與方式包括(例如)經口、經頰、舌下及直腸投與。經上皮投與方式包括(例如)經黏膜投與及經皮投與。經黏膜投與包括(例如)腸內投與以及經鼻、吸入及深肺投與;經陰道投與;及經頰及舌下投與。經皮投與包括被動或主動經皮或透皮方式,包括例如貼劑及離子電滲裝置,以及膏糊、油膏或軟膏劑之局部施加。非經腸投與亦可使用高壓技術(例如POWD ERJECTTM)來完成。
可經由臨床前活體外及活體內研究收集關於本文所述化合物(I)之鹽或共晶體形式及本文所述化合物(I)之鹽或共晶體形式之調配物的藥物動力學及藥效學資訊,稍後在臨床試驗過程期間在人類中確認。因此,對於本文所述方法中所用之本文所述化合物(I)之鹽或共晶體形式,可最初自生物化學及/或基於細胞之分析估計治療有效劑量。接著,可在動物模型中調配劑量以達成調節BTK表現或活性之合意之循環濃度範圍。在執行人類研究時,將出現關於對於各種疾病及病況適當劑量值及治療之持續時間的其他資訊。
該等化合物之毒性及治療功效可在細胞培養物或實驗動物中藉由標準醫藥程序來測定,例如測定LD50(可導致群體中之50%死亡之劑量)及ED50(對群體中之50%治療有效之劑量)的程序。毒性及治療效應之間之劑量比率即為「治療指數」,其通常表示為比率LD50/ED50。展現較大治療指數之化合物(亦即毒性劑量實質上高於有效劑量)較佳。可在調配供人類使用之劑量範圍中使用自該等細胞培養分析及額外動物研究獲得之數據。該等化合物之劑量較佳位於具有極 低毒性或無毒性之循環濃度(包括ED50)範圍內。
應理解,可使用調節劑量之時間及順序之任何有效投與方案。本文所述化合物(I)之鹽或共晶體形式及其醫藥組合物可包括其中活性成分係有效量投與以達成其預期目的之彼等。在一些實施例中,「治療有效量」意指足以調節BTK表現或活性(包括)且藉此治療患有適應症之個體(例如,人類)或緩和適應症之現存症狀的量。
人類個體之實例性劑量值係大約約0.001毫克活性劑/公斤體重(mg/kg)至約1000mg/kg。通常,端視(例如)適應症、投與途徑及病況之嚴重程度而定,活性劑之劑量單位包含約0.01mg至約1000mg、較佳約0.1mg至約100mg。端視投與途徑而定,可根據體重/體表面積或器官大小計算適宜劑量。最終劑量方案係由主治醫師鑒於良好醫療實踐考慮各種因素來確定:該等因素改良藥物作用,例如化合物之比活性、疾病狀態之屬性(identity)及嚴重程度、個體之反應性、個體之年齡、病況、體重、性別及飲食及任何感染之嚴重程度。可慮及之額外因素包括投與之時間及頻率、藥物組合、反應敏感性及對療法之耐受性/反應。涉及本文提及之調配物中之任一者之適於治療之劑量之進一步精化通常由熟練從業者而無需過多實驗、尤其鑒於所揭示之劑量資訊及分析以及人類臨床試驗中觀察之藥物動力學數據來進行。適當劑量可經由使用測定體液或其他樣品內之試劑之濃度的確立分析以及劑量反應數據來確定。
投藥頻率取決於試劑之藥物動力學參數及投與途徑。調節劑量及投與以提供足夠量之活性部分或維持期望效應。因此,醫藥組合物可以維持試劑之期望最小量所需之單一劑量、多個離散劑量、連續輸注、持續釋放儲積物或其組合來投與。短效醫藥組合物(即,短的半衰期)可每天一次或每天一次以上(例如,每天兩次、三次或四次)投與。長效醫藥組合物可每3至4天、每週或每兩週一次投與。
提供本文所述化合物(I)之鹽或共晶體形式及或本文所述其組合物用於以治療或預防方式選擇性或特異性抑制BTK活性的用途。方法包含向有需要之個體(例如,人類)投與足以抑制BTK活性之量之本文所述化合物(I)之鹽或共晶體形式或其組合物。方法可用於治療患有或遭受症狀或病狀係由BTK表現或活性介導之病況的人類或動物。
「治療」(「treatment」或「treating」)係獲得有益或期望結果(包括臨床結果)之方法。有益或期望臨床結果可包括以下中之一或多者:(i)減少自該疾病產生之一或多種症狀;(ii)降低疾病之程度及/或穩定疾病(例如,延遲疾病之惡化);(iii)延遲疾病之擴散(例如,轉移);(iv)延遲或減緩疾病復發及/或疾病之進展;(v)改善疾病狀態及/或提供疾病之緩解(部分或完全)及/或減少治療疾病所需之一或多種其他藥劑之劑量;(vi)提高生活品質,及/或(vii)延長存活期。
在一些實施例中,「病症」意欲涵蓋(但不限於)醫學病症、疾病、病況、症候群及諸如此類。本申請案中揭示之方法涵蓋治療動物個體、較佳哺乳動物、更佳靈長類動物且仍更佳人類之各種方式。可治療之哺乳動物係(例如)人類;伴侶動物(寵物),包括動物及貓;農場動物,包括牛、馬、綿羊、豬及山羊;實驗室動物,包括大鼠、小鼠、兔、天竺鼠及非人類靈長類動物;及動物園樣本。可治療之非哺乳動物包括(例如)鳥類、魚、爬行動物及兩棲動物。
在一態樣中,本文所述化合物(I)之鹽或共晶體形式及本文所述其組合物可用於抑製造血來源之癌細胞(例如癌細胞)之生長或增殖的方法中。在一些 實施例中,癌細胞具有淋巴來源,且在具體實施例中,癌細胞與B淋巴球或B淋巴球祖細胞有關或源自B淋巴球或B淋巴球祖細胞。在另一態樣中,本文所述化合物(I)之鹽或共晶體形式及本文所述其組合物可用於治療患有癌症之人類之方法中。
適於使用本申請案中揭示之方法治療之癌症包括(例如)非霍奇金氏淋巴瘤(non-Hodgkin's lymphomas),其中B細胞非霍奇金氏淋巴瘤尤其適宜,例如柏基特氏淋巴瘤(Burkitt's lymphoma)、AIDS相關之淋巴瘤、邊緣區B細胞淋巴瘤(結節邊緣區B細胞淋巴瘤、結節外邊緣區B細胞淋巴瘤及脾邊緣區B細胞淋巴瘤)、瀰漫性大B細胞淋巴瘤、原發性積液淋巴瘤、淋巴瘤樣肉芽腫病、濾泡性淋巴瘤、B細胞慢性淋巴球性白血病、B細胞前淋巴球性白血病、淋巴漿細胞白血病/華氏巨球蛋白血症(Waldenstrom's macroglobulinemia)、漿細胞瘤、外套細胞淋巴瘤、縱膈大B細胞淋巴瘤、血管內大B細胞淋巴瘤及毛細胞白血病。除了非霍奇金氏淋巴瘤外,本發明中之癌症包括胰臟內分泌腫瘤,例如胰島素瘤、胃泌素瘤、胰升糖素瘤、體抑素瘤、VIP瘤、PP瘤及GRF瘤。亦可藉由投與本文所述化合物(I)之鹽或共晶體形式及本文所述其組合物治療造血來源或其他來源之表現BTK之其他癌細胞。
在另一態樣中,本文所述化合物(I)之鹽或共晶體形式及本文所述其組合物可用於治療自體免疫疾病之方法中。在特定實施例中,自體免疫疾病係發炎性腸病、關節炎、狼瘡、類風濕性關節炎、牛皮癬關節炎、骨關節炎、斯蒂爾氏病(Still's disease)、青少年關節炎、I型糖尿病、重症肌無力、橋本氏甲狀腺炎(Hashimoto's thyroiditis)、奧德氏甲狀腺炎(Ord's thyroiditis)、巴塞杜氏病(Basedow's disease)、薛格連氏症候群(Sjögren's syndrome)、多發性硬化、格林-巴利症候群(Guillain-Barré syndrome)、急性瀰漫性腦脊髓炎、艾迪森氏病(Addison's disease)、視性眼陣攣-肌陣攣症候群、關節黏連性脊椎炎、抗磷脂抗 體症候群、再生障礙性貧血、自體免疫肝炎、乳糜瀉、古巴士德氏症候群(Goodpasture's syndrome)、特發性血小板減少紫斑症、視神經炎、硬皮症、原發性膽汁性肝硬化、雷特氏病(Reiter's disease)、高安動脈炎(Takayasu's arteritis)、顳動脈炎、溫抗體型自體免疫溶血性貧血、韋格納氏肉芽腫(Wegener's granuloma)、牛皮癬、普禿、貝歇氏病(Behget's disease)、慢性疲勞症候群、自主神經機能異常、子宮內膜異位症、間質性膀胱炎、肌強直、陰唇痛症及全身性紅斑狼瘡。
在另一態樣中,提供藉由向患有BTK介導之病症之人類投與本文所述化合物(I)之鹽或共晶體形式來治療該人類的方法。亦提供藉由投與本文所述化合物(I)之鹽或共晶體形式調節個體之BTK的方法。在一種變化形式中,人類患有癌症,例如白血病或淋巴瘤。在另一變化形式中,人類患有自體免疫疾病,例如氣喘、類風濕性關節炎、多發性硬化或狼瘡。
本文所述化合物可與以下中之一或多者一起使用或組合:化學治療劑、抗癌劑、抗血管生成劑、抗纖維變性劑、免疫治療劑、治療性抗體、雙特異性抗體及「抗體樣」治療性蛋白、抗體-藥物偶聯物(ADC)、放射性治療劑、抗瘤劑、抗增殖劑、溶瘤病毒、基因修飾劑或編輯劑(例如CRISPR(包括CRISPR Cas9))、鋅指核酸酶或合成核酸酶(TALEN)、CAR(嵌合抗原受體)T-細胞免疫治療劑或其任一組合。該等治療劑可呈化合物、抗體、多肽或多核苷酸形式。在一個實施例中,本申請案提供包含本文所述化合物及額外治療劑之產物,其作為同時、單獨或依序用於療法(例如,治療由BTK介導之疾病、病症或病況之方法)中之組合製劑。
一或多種治療劑包括(但不限於)基因、配體、受體、蛋白質、諸如以下等因子之抑制劑、激動劑、拮抗劑、配體、調節劑、刺激物、阻斷劑、活化劑或阻抑劑:愛柏森(Abelson)鼠類白血病病毒致癌基因同系物1基因(ABL,例如ABL1)、乙醯基-CoA羧化酶(例如ACC1/2)、活化CDC激酶(ACK,例如ACK1)、 腺苷去胺酶、腺苷受體(例如A2B、A2a、A3)、腺苷酸環化酶、ADP核糖基環化酶-1、促腎上腺皮質激素受體(ACTH)、氣單胞菌溶素、AKT1基因、Alk-5蛋白激酶、鹼性磷酸酶、α1腎上腺素受體、α2腎上腺素受體、α-酮戊二酸去氫酶(KGDH)、胺基肽酶N、AMP活化之蛋白激酶、退行發育性淋巴瘤激酶(ALK,例如ALK1)、雄激素受體、血管生成素(例如配體-1、配體-2)、血管緊張素原(AGT)基因、鼠類胸腺瘤病毒致癌基因同系物1(AKT)蛋白激酶(例如AKT1、AKT2、AKT3)、載脂蛋白A-I(APOA1)基因、細胞凋亡誘導因子、細胞凋亡蛋白(例如1、2)、細胞凋亡信號調節激酶(ASK,例如ASK1)、精胺酸酶(I)、精胺酸脫亞胺酶、芳香酶、星樣同系物1(ASTE1)基因、共濟失調毛細管擴張及Rad 3相關(ATR)絲胺酸/蘇胺酸蛋白激酶、Aurora蛋白激酶(例如1、2)、Axl酪胺酸激酶受體、含桿狀病毒IAP重複5(BIRC5)基因、巴斯金(Basigin)、B細胞淋巴瘤2(BCL2)基因、Bcl2結合組分3、Bcl2蛋白、BCL2L11基因、BCR(斷點簇區)蛋白及基因、β腎上腺素受體、β-連環蛋白、B-淋巴球抗原CD19、B-淋巴球抗原CD20、B-淋巴球細胞黏著分子、B-淋巴球刺激物配體、骨形態演發蛋白-10配體、骨形態演發蛋白-9配體調節劑、Brachyury蛋白、緩激肽受體、B-Raf原癌基因(BRAF)、Brc-Abl酪胺酸激酶、含有溴結構域及外結構域(BET)溴結構域之蛋白(例如BRD2、BRD3、BRD4)、攜鈣蛋白、攜鈣蛋白依賴性蛋白激酶(CaMK,例如CAMKII)、癌睪丸抗原2、癌睪丸抗原NY-ESO-1、癌/睪丸抗原1B(CTAG1)基因、大麻素受體(例如CB1、CB2)、碳酸酐酶、酪蛋白激酶(CK,例如CKI、CKII)、半胱天冬酶(例如半胱天冬酶-3、半胱天冬酶-7、半胱天冬酶-9)、半胱天冬酶8細胞凋亡相關半胱胺酸肽酶CASP8-FADD樣調節劑、半胱天冬酶募集結構域蛋白-15、細胞自溶酶G、CCR5基因、CDK活化激酶(CAK)、檢查點激酶(例如CHK1、CHK2)、趨化介素(C-C基序)受體(例如CCR2、CCR4、CCR5)、趨化介素(C-X-C基序)受體(例如CXCR4、CXCR1及CXCR2)、趨化介素CC21配體、膽囊收縮 素CCK2受體、絨毛膜促性腺激素、c-Kit(酪胺酸-蛋白激酶Kit或CD117)、密連蛋白(例如6、18)、分化簇(CD),例如CD4、CD27、CD29、CD30、CD33、CD37、CD40、CD40配體受體、CD40配體、CD40LG基因、CD44、CD45、CD47、CD49b、CD51、CD52、CD55、CD58、CD66e、CD70基因、CD74、CD79、CD79b、CD79B基因、CD80、CD95、CD99、CD117、CD122、CDw123、CD134、CDw137、CD158a、CD158b1、CD158b2、CD223、CD276抗原;叢生蛋白(CLU)基因、叢生蛋白、c-Met(肝細胞生長因子受體(HGFR))、補體C3、結締組織生長因子、COP9信號小體亞單位5、CSF-1(群落刺激因子1受體)、CSF2基因、CTLA-4(細胞毒性T-淋巴球蛋白4)受體、週期蛋白D1、週期蛋白G1、週期蛋白依賴性激酶(CDK,例如CDK1、CDK1B、CDK2-9)、環加氧酶(例如1、2)、CYP2B1基因、豪豬半胱胺酸棕櫚醯基轉移酶、細胞色素P450 11B2、細胞色素P450 17、細胞色素P450 17A1、細胞色素P450 2D6、細胞色素P450 3A4、細胞色素P450還原酶、細胞介素信號傳導-1、細胞介素信號傳導-3、細胞質異檸檬酸鹽去氫酶、胞嘧啶去胺酶、胞嘧啶DNA甲基轉移酶、細胞毒性T-淋巴球蛋白-4、DDR2基因、δ樣蛋白配體(例如3、4)、去氧核糖核酸酶、Dickkopf-1配體、二氫葉酸還原酶(DHFR)、二氫嘧啶去氫酶、二肽基肽酶IV、盤狀結構域受體(DDR,例如DDR1)、DNA結合蛋白(例如HU-β)、DNA依賴性蛋白激酶、DNA迴旋酶、DNA甲基轉移酶、DNA聚合酶(例如α)、DNA引發酶、dUTP焦磷酸酶、L-多巴色素互變異構酶、棘皮動物微管樣蛋白4、EGFR酪胺酸激酶受體、彈性蛋白酶、延長因子1 α 2、延長因子2、內皮因子、內核酸酶、內質網素、內皮唾酸蛋白、內皮抑素、內皮素(例如ET-A、ET-B)、zeste同系物2增強子(EZH2)、Ephrin(EPH)酪胺酸激酶(例如Epha3、Ephb4)、Ephrin B2配體、表皮生長因子、表皮生長因子受體(EGFR)、表皮生長因子受體(EGFR)基因、表皮素、上皮細胞黏著分子(EpCAM)、Erb-b2(v-erb-b2禽類成紅血球細胞白血病病毒致癌基因同系物2)酪 胺酸激酶受體、Erb-b3酪胺酸激酶受體、Erb-b4酪胺酸激酶受體、E-選擇蛋白、雌二醇17 β去氫酶、雌激素受體(例如α、β)、雌激素相關受體、真核轉譯起始因子5A(EIF5A)基因、輸出蛋白1、細胞外信號相關激酶(例如1、2)、細胞外信號調節激酶(ERK)、因子(例如Xa、VIIa)、類法呢醇(farnesoid)x受體(FXR)、Fas配體、脂肪酸合酶、鐵蛋白、FGF-2配體、FGF-5配體、成纖維細胞生長因子(FGF,例如FGF1、FGF2、FGF4)、纖連蛋白、Fms相關酪胺酸激酶3(Flt3)、黏著斑激酶(FAK,例如FAK2)、葉酸鹽水解酶前列腺特異性膜抗原1(FOLH1)、葉酸鹽受體(例如α)、葉酸鹽、葉酸鹽運輸蛋白1、FYN酪胺酸激酶、成對鹼性胺基酸裂解酶(弗林蛋白酶(FURIN))、β-葡萄糖醛酸苷酶、半乳糖轉移酶、半乳糖凝集素-3、糖皮質激素、糖皮質激素誘導之TNFR相關蛋白GITR受體、麩胺酸鹽羧肽酶II、麩胺醯胺酶、麩胱甘肽S-轉移酶P、肝醣合酶激酶(GSK,例如3-β)、磷脂醯肌醇聚糖3(GPC3)、促性腺激素釋放激素(GNRH)、顆粒球巨噬細胞群落刺激因子(GM-CSF)受體、顆粒球-群落刺激因子(GCSF)配體、生長因子受體結合之蛋白2(GRB2)、Grp78(78kDa葡萄糖調節之蛋白)鈣結合蛋白、分子伴護蛋白groEL2基因、熱休克蛋白(例如27、70、90 α、β)、熱休克蛋白基因、熱穩定腸毒素受體、刺蝟(Hedgehog)蛋白、類肝素酶、肝細胞生長因子、HERV-H LTR相關蛋白2、己糖激酶、組織胺H2受體、組織蛋白甲基轉移酶(DOT1L)、組織蛋白去乙醯酶(HDAC,例如1、2、3、6、10、11)、組織蛋白H1、組織蛋白H3、HLA I類抗原(A-2 α)、HLA II類抗原、同源異形盒蛋白NANOG、HSPB1基因、人類白血球抗原(HLA)、人類乳頭瘤病毒(例如E6、E7)蛋白、玻尿酸、玻尿酸酶、缺氧誘導之因子-1 α、印跡母系表現轉錄(H19)基因、促分裂原活化之蛋白激酶激酶激酶激酶1(MAP4K1)、酪胺酸-蛋白激酶HCK、I-κ-B激酶(IKK,例如IKKbe)、IL-1 α、IL-1 β、IL-12、IL-12基因、IL-15、IL-17、IL-2基因、IL-2受體α亞單位、IL-2、IL-3受體、IL-4、IL-6、IL-7、IL-8、免疫球蛋白(例如G、G1、G2、 K、M)、免疫球蛋白Fc受體、免疫球蛋白γFc受體(例如I、III、IIIA)、吲哚胺2,3-雙加氧酶(IDO,例如IDO1)、吲哚胺吡咯2,3-雙加氧酶1抑制劑、胰島素受體、胰島素樣生長因子(例如1、2)、整聯蛋白α-4/β-1、整聯蛋白α-4/β-7、整聯蛋白α-5/β-1、整聯蛋白α-V/β-3、整聯蛋白α-V/β-5、整聯蛋白α-V/β-6、細胞間黏著分子1(ICAM-1)、干擾素(例如α、α 2、β、γ)、干擾素誘導蛋白黑色素瘤缺失因子2(AIM2)、干擾素I型受體、介白素1配體、介白素13受體α 2、介白素2配體、介白素-1受體相關之激酶4(IRAK4)、介白素-2、介白素-29配體、異檸檬酸鹽去氫酶(例如IDH1、IDH2)、傑納斯激酶(Janus kinase,JAK,例如JAK1、JAK2)、Jun N末端激酶、激肽釋放酶相關肽酶3(KLK3)基因、殺傷細胞Ig樣受體、激酶插入結構域受體(KDR)、驅動蛋白樣蛋白KIF11、Kirsten大鼠肉瘤病毒致癌基因同系物(KRAS)基因、親吻促動素(KiSS-1)受體、KIT基因、v-kit Hardy-Zuckerman 4貓肉瘤病毒致癌基因同系物(KIT)酪胺酸激酶、乳鐵蛋白、羊毛固醇-14去甲基酶、LDL受體相關蛋白-1、白三烯A4水解酶、李斯特菌素(Listeriolysin)、L-選擇蛋白、黃體促素受體、裂合酶、淋巴球活化基因3蛋白(LAG-3)、淋巴球抗原75、淋巴球功能抗原-3受體、淋巴球特異性蛋白酪胺酸激酶(LCK)、淋巴細胞趨化蛋白、Lyn(Lck/Yes新穎)酪胺酸激酶、離胺酸去甲基酶(例如KDM1、KDM2、KDM4、KDM5、KDM6、A/B/C/D)、溶血磷脂酸(Lysophosphatidate)-1受體、溶酶體相關膜蛋白家族(LAMP)基因、離胺醯氧化酶同系物2、離胺醯氧化酶蛋白(LOX)、離胺醯氧化酶樣蛋白(LOXL,例如LOXL2)、造血祖細胞激酶1(HPK1)、肝細胞生長因子受體(MET)基因、巨噬細胞群落-刺激因子(MCSF)配體、巨噬細胞遷移抑制性因子、MAGEC1基因、MAGEC2基因、窿體主蛋白、MAPK活化之蛋白激酶(例如MK2)、Mas相關G蛋白偶聯受體、基質金屬蛋白酶(MMP,例如MMP2、MMP9)、Mcl-1分化蛋白、Mdm2 p53結合蛋白、Mdm4蛋白、Melan-A(MART-1)黑色素瘤抗原、黑色素細胞蛋白Pmel 17、黑色素細胞刺激激素配體、黑色素瘤抗原家族A3(MAGEA3)基因、黑色素瘤相關抗原(例如1、2、3、6)、膜銅胺氧化酶、間皮素、MET酪胺酸激酶、促代謝型麩胺酸受體1、金屬還原酶STEAP1(前列腺1之六跨膜上皮抗原)、轉移抑素、甲硫胺酸胺基肽酶-2、甲基轉移酶、粒線體3酮脂醯CoA硫解酶、促分裂原活化蛋白激酶(MAPK)、促分裂原活化之蛋白激酶(MEK,例如MEK1、MEK2)、mTOR(雷帕黴素(rapamycin)之機械靶標(絲胺酸/蘇胺酸激酶)、mTOR複合物(例如1、2)、黏蛋白(例如1、5A、16)、mut T同系物(MTH,例如MTH1)、Myc原癌基因蛋白、骨髓細胞白血病1(MCL1)基因、肉豆蔻醯酸化富丙胺酸蛋白激酶C受質(MARCKS)蛋白、NAD ADP核糖基轉移酶、利鈉肽受體C、中性細胞黏著分子1、神經激肽1(NK1)受體、神經激肽受體、跨膜蛋白2、NF κ B活化蛋白、NIMA相關激酶9(NEK9)、一氧化氮合酶、NK細胞受體、NK3受體、NKG2 A B活化NK受體、去甲腎上腺素運輸蛋白、Notch(例如Notch-2受體、Notch-3受體)、核紅血球2相關因子2、核因子(NF)κ B、核仁素、核磷蛋白、核磷蛋白-退行發育性淋巴瘤激酶(NPM-ALK)、2酮戊二酸去氫酶、2,5-寡腺苷酸合成酶、O-甲基鳥嘌呤DNA甲基轉移酶、類鴉片受體(例如δ)、鳥胺酸去羧酶、乳清酸鹽磷酸核糖基轉移酶、孤核激素受體NR4A1、骨鈣化素、破骨細胞分化因子、骨橋蛋白、OX-40(腫瘤壞死因子受體超家族成員4 TNFRSF4或CD134)受體、P3蛋白、p38激酶、p38 MAP激酶、p53腫瘤抑制劑蛋白、副甲狀腺激素配體、過氧化體增殖物活化之受體(PPAR,例如α、δ、γ)、P-醣蛋白(例如1)、磷酸酶及張力蛋白同系物(PTEN)、磷脂醯肌醇3-激酶(PI3K)、磷酸肌醇-3激酶(PI3K,例如α、δ、γ)、磷酸化酶激酶(PK)、PKN3基因、胎盤生長因子、血小板源生長因子(PDGF,例如α、β)、血小板源生長因子(PDGF,例如α、β)、多向性抗藥性運輸蛋白、神經叢蛋白B1、PLK1基因、polo樣激酶(PLK)、Polo樣激酶1、聚ADP核糖聚合酶(PARP,例如PARP1、2及3)、黑色素瘤中優先表 現之抗原(PRAME)基因、異戊二烯基結合蛋白(PrPB)、可能之轉錄因子PML、助孕酮受體、程式化細胞死亡1(PD-1)、程式化細胞死亡配體1抑制劑(PD-L1)、前塞波素(Prosaposin)(PSAP)基因、類前列腺素受體(EP4)、前列腺特異性抗原、前列腺酸磷酸酶、蛋白酶體、蛋白E7、蛋白法尼基轉移酶、蛋白激酶(PK,例如A、B、C)、蛋白酪胺酸激酶、蛋白酪胺酸磷酸酶β、原癌基因絲胺酸/蘇胺酸-蛋白激酶(PIM,例如PIM-1、PIM-2、PIM-3)、P-選擇蛋白、嘌呤核苷磷酸化酶、嘌呤能受體P2X配體門控之離子通道7(P2X7)、丙酮酸鹽去氫酶(PDH)、丙酮酸鹽去氫酶激酶、丙酮酸鹽激酶(PYK)、5-α-還原酶、Raf蛋白激酶(例如1、B)、RAF1基因、Ras基因、Ras GTPase、RET基因、Ret酪胺酸激酶受體、視網膜母細胞瘤相關之蛋白、視黃酸受體(例如γ)、類視色素X受體、Rheb(腦中富含之Ras同系物)GTPase、Rho(Ras同系物)相關之蛋白激酶2、核糖核酸酶、核糖核苷酸還原酶(例如M2亞單位)、核糖體蛋白S6激酶、RNA聚合酶(例如I、II)、Ron(Recepteur d'Origine Nantais)酪胺酸激酶、ROS1(ROS原癌基因1、受體酪胺酸激酶)基因、Ros1酪胺酸激酶、Runt相關轉錄因子3、γ-分泌酶、S100鈣結合蛋白A9、肌漿內質鈣ATPase、半胱天冬酶之第二線粒體源活化劑(SMAC)蛋白、分泌型捲曲相關蛋白-2、信號素-4D、絲胺酸蛋白酶、絲胺酸/蘇胺酸激酶(STK)、絲胺酸/蘇胺酸-蛋白激酶(TBK,例如TBK1)、信號轉導及轉錄(STAT,例如STAT-1、STAT-3、STAT-5)、信號傳導淋巴球性活化分子(SLAM)家族成員7、前列腺之六跨膜上皮抗原(STEAP)基因、SL細胞介素配體、平滑(SMO)受體、碘化鈉共運輸蛋白、磷酸鈉共運輸蛋白2B、體抑素受體(例如1、2、3、4、5)、音猥蛋白、特異性蛋白1(Sp1)轉錄因子、鞘磷脂合酶、神經鞘胺醇激酶(例如1、2)、神經鞘胺醇-1-磷酸鹽受體-1、脾酪胺酸激酶(SYK)、SRC基因、Src酪胺酸激酶、STAT3基因、類固醇硫酸酯酶、干擾素基因之刺激物(STING)受體、干擾素基因蛋白之刺激物、基質細胞源因子1配體、SUMO(小泛蛋白樣修飾劑)、超 氧化物歧化酶、存活素蛋白、突觸蛋白3、多配體聚醣-1、突觸核蛋白α、T細胞表面醣蛋白CD28、tank-結合激酶(TBK)、TATA盒結合蛋白相關因子RNA聚合酶I亞單位B(TAF1B)基因、T細胞CD3醣蛋白ζ鏈、T細胞分化抗原CD6、含T細胞免疫球蛋白及黏蛋白-結構域3(TIM-3)、T細胞表面醣蛋白CD8、Tec蛋白酪胺酸激酶、Tek酪胺酸激酶受體、端粒酶、端粒酶反轉錄酶(TERT)基因、腱醣蛋白、TGF β 2配體、促血小板生成素受體、胸苷激酶、胸苷磷酸化酶、胸腺嘧啶核苷酸合酶、胸腺嘧啶核苷酸合酶、胸腺素(例如α 1)、甲狀腺激素受體、甲狀腺刺激激素受體、組織因子、TNF相關細胞凋亡誘導配體、TNFR1相關死亡結構域蛋白、TNF相關細胞凋亡誘導配體(TRAIL)受體、TNFSF11基因、TNFSF9基因、類鐸受體(TLR,例如1-13)、拓樸異構酶(例如I、II、III)、轉錄因子、轉移酶、運鐵蛋白、轉變生長因子(TGF,例如β)激酶、轉變生長因子TGF-β受體激酶、轉麩醯胺酸酶、易位相關之蛋白、跨膜醣蛋白NMB、Trop-2鈣信號轉換器、滋養層醣蛋白(TPBG)基因、滋養層醣蛋白、原肌球蛋白受體激酶(Trk)受體(例如TrkA、TrkB、TrkC)、色胺酸5-羥化酶、微管蛋白、腫瘤壞死因子(TNF,例如α、β)、腫瘤壞死因子13C受體、腫瘤進展基因座2(TPL2)、腫瘤蛋白53(TP53)基因、腫瘤抑制劑候選者2(TUSC2)基因、酪胺酸酶、酪胺酸羥化酶、酪胺酸激酶(TK)、酪胺酸激酶受體、具有免疫球蛋白樣及EGF樣結構域(TIE)受體之酪胺酸激酶、酪胺酸蛋白激酶ABL1抑制劑、泛蛋白、泛蛋白羧基水解酶同功酶L5、泛蛋白硫酯酶-14、泛蛋白偶聯酶E2I(UBE2I、UBC9)、尿素酶、尿激酶纖維蛋白溶酶原活化劑、子宮珠蛋白、類香草素VR1、血管細胞黏著蛋白1、血管內皮生長因子受體(VEGFR)、T細胞活化之V-結構域Ig抑制劑(VISTA)、VEGF-1受體、VEGF-2受體、VEGF-3受體、VEGF-A、VEGF-B、波形蛋白、維生素D3受體、原癌基因酪胺酸-蛋白激酶Yes、Wee-1蛋白激酶、威爾姆氏腫瘤(Wilms' tumor)抗原1、威爾姆氏腫瘤蛋白、細胞凋亡蛋白之X鏈接之抑制劑、鋅指蛋白 轉錄因子或其任一組合。
一個態樣提供藉由向患有BTK介導之病症之人類投與式(I)-(III)之BTK抑制劑與一或多種選自以下之群之其他治療劑之組合來治療該人類的方法:細胞凋亡信號調節激酶(ASK)抑制劑、盤狀結構域受體(DDR)抑制劑、組織蛋白去乙醯酶(HDAC)抑制劑、傑納斯激酶(JAK)抑制劑、離胺醯氧化酶樣蛋白2(LOXL2)抑制劑、基質金屬蛋白酶9(MMP9)抑制劑、磷脂醯肌醇3-激酶(PI3K)抑制劑、脾酪胺酸激酶(SYK)抑制劑、BET-溴結構域4(BRD4)抑制劑、檢查點抑制劑、B細胞慢性淋巴球性白血病(CLL)/淋巴瘤2(BCL-2)抑制劑及CD20抑制劑。在上述方法中之任一者中,式(I)-(III)之BTK抑制劑可作為單位劑量、例如以錠劑形式如本文所述投與個體。同樣,在上述方法中之任一者中,式(I)-(III)之BTK抑制劑及一或多種治療劑可同時或依序投與。
一或多種治療劑之實例包括(但不限於)ASK抑制劑,包括ASK1抑制劑,例如WO 2011/008709及WO 2013/112741中所述之彼等;CD47抑制劑,例如抗CD47 mAbs(Vx-1004)、抗人類CD47 mAb(CNTO-7108)、CC-90002、CC-90002-ST-001、人類化抗CD47抗體(Hu5F9-G4)、NI-1701、NI-1801、RCT-1938及TTI-621;CDK抑制劑,例如阿博馬昔地(abemaciclib)、阿伏昔地(alvocidib)(HMR-1275、夫拉平度(flavopiridol))、AT-7519、FLX-925、LEE001、帕博西尼(palbociclib)、利泊昔布(ribociclib)、瑞格色替(rigosertib)、塞林克(selinexor)、UCN-01及TG-02;DDR抑制劑,例如PCT專利第WO 2014/047624號、第WO 2013/027802號及第WO 2013/034933號、美國公開專利申請案第2011/0287011號及第2009/0142345中揭示之彼等;HDAC抑制劑,例如阿貝司他(abexinostat)、ACY-241、AR-42、BEBT-908、貝林司他(belinostat)、CKD-581、CS-055(HBI-8000)、CUDC-907、恩替諾特(entinostat)、吉維司他(givinostat)、莫賽替諾司他(mocetinostat)、帕比司他(pracinostat)、普西司他(pracinostat)、奎司司他(quisinostat) (JNJ-26481585)、瑞米司他(resminostat)、瑞可諾司他(ricolinostat)、SHP-141、丙戊酸(VAL-001)、伏立諾他(vorinostat);IDO1抑制劑,例如BLV-0801、艾帕卡得司他(epacadostat)、F-001287、GBV-1012、GBV-1028、GDC-0919、吲哚西莫(indoximod)、NKTR-218、基於NLG-919之疫苗、PF-06840003、吡喃并萘并醌衍生物(SN-35837)、瑞米司他(resminostat)、SBLK-200802及shIDO-ST;JAK抑制劑,例如AT9283、AZD1480、巴瑞替尼(baricitinib)、BMS-911543、非曲替尼(fedratinib)、非哥替尼(filgotinib)(GLPG0634)、甘多替尼(gandotinib)(LY2784544)、INCB039110、來他替尼(lestaurtinib)、莫羅替尼(momelotinib)(CYT0387)、NS-018、帕克替尼(pacritinib)(SB1518)、派非西替尼(peficitinib)(ASP015K)、魯索替尼、托法替尼(tofacitinib)(先前稱作他索替尼(tasocitinib))及XL019;LOXL抑制劑,例如WO 2009/017833、WO 2009/035791及WO 2011/097513中所述之抗體;MMP9抑制劑,例如馬立馬司他(marimastat)(BB-2516)、西馬司他(cipemastat)(Ro 32-3555)及闡述於PCT公開案第WO 2012/027721號中之彼等;MEK抑制劑,例如安卓奎諾爾(antroquinonol)、比尼替尼(binimetinib)、考比替尼(cobimetinib)(GDC-0973、XL-518)、MT-144、司美替尼(selumetinib)(AZD6244)、索拉菲尼(sorafenib)、曲美替尼(trametinib)(GSK1120212)、阿普色替(uprosertib)+曲美替尼;PI3K抑制劑,例如ACP-319、AEZA-129、AMG-319、AS252424、AZD8186、BAY 10824391、BEZ235、布帕里斯(buparlisib)(BKM120)、BYL719(alpelisib(alpelisib))、CH5132799、庫潘里斯(copanlisib)(BAY 80-6946)、杜維里斯(duvelisib)、GDC-0941、GDC-0980、GSK2636771、GSK2269557、艾代拉里斯(idelalisib)(Zydelig®)、IPI-145、IPI-443、IPI-549、KAR4141、LY294002、LY3023414、MLN1117、OXY111A、PA799、PX-866、RG7604、瑞格色替、RP5090、他塞里斯(taselisib)、TG100115、TGR-1202、TGX221、WX-037、X-339、X-414、XL147(SAR245408)、XL499、XL756、渥曼青黴素(wortmannin)、ZSTK474及 闡述於PCT公開案第WO 2005/113556號、第WO 2013/052699號、第WO 2013/116562號、第WO 2014/100765號、第WO 2014/100767號及第WO 2014/201409號中之化合物;SYK抑制劑,例如6-(1H-吲唑-6-基)-N-(4-嗎啉基苯基)咪唑并[1,2-a]吡嗪-8-胺、BAY-61-3606、賽杜替尼(cerdulatinib)(PRT-062607)、恩特替尼(entospletinib)、福他替尼(fostamatinib)(R788)、HMPL-523、NVP-QAB 205 AA、R112、R343、他馬替尼(tamatinib)(R406)及闡述於美國專利第8,450,321號及美國公開專利申請案第2015/0175616號中之彼等;TLR8抑制劑,例如E-6887、IMO-4200、IMO-8400、IMO-9200、MCT-465、MEDI-9197、莫托莫德(motolimod)、雷西莫特(resiquimod)、VTX-1463及VTX-763;TLR9抑制劑,例如IMO-2055、IMO-2125、來非特利莫德(lefitolimod)、利尼莫德(litenimod)、MGN-1601及PUL-042;TKI抑制劑,例如阿法替尼(afatinib)、ARQ-087、asp5878、AZD3759、AZD4547、伯舒替尼(bosutinib)、博瑞加替尼(brigatinib)、卡博替尼(cabozantinib)、西地尼布(cediranib)、克萊拉尼(crenolanib)、達克替尼(dacomitinib)、達沙替尼(dasatinib)、多韋替尼(dovitinib)、E-6201、厄達替尼(erdafitinib)、厄洛替尼(erlotinib)、吉非替尼(gefitinib)、吉特替尼(gilteritinib)(ASP-2215)、FP-1039、HM61713、埃克替尼(icotinib)、伊馬替尼(imatinib)、KX2-391(Src)、拉帕替尼(lapatinib)、來他替尼、米哚妥林(midostaurin)、尼達尼布(nintedanib)、ODM-203、奧希替尼(osimertinib)(AZD-9291)、普納替尼(ponatinib)、泊西替尼(poziotinib)、奎紮替尼(quizartinib)、拉多替尼(radotinib)、盧塞替尼(rociletinib)、索凡替尼(sulfatinib)(HMPL-012)、舒尼替尼(sunitinib)及TH-4000。
如本文所用術語「化學治療劑」或「化學治療性」(或在經化學治療劑治療之情形下「化學療法」)意指涵蓋可用於治療癌症之任何非蛋白質性(即非肽性)化學化合物。化學治療劑之實例包括但不限於:烷基化劑,例如噻替派(thiotepa)及環磷醯胺(CYTOXAN®);磺酸烷基酯,例如白消安(busulfan)、英丙 舒凡(improsulfan)及哌泊舒凡(piposulfan);氮丙啶,例如苯并多巴(benzodepa)、卡波醌(carboquone)、美妥替派(meturedepa)及烏瑞替派(uredepa);次乙亞胺及甲基蜜胺,包括六甲蜜胺(alfretamine)、三伸乙基三聚氰胺、三伸乙基磷醯胺、三伸乙基硫代磷醯胺及三羥甲基蜜胺;番荔枝內酯(acetogenin),尤其係布拉他辛(bullatacin)及布拉他辛酮(bullatacinone);喜樹鹼(camptothecin),包括合成類似物托泊替康(topotecan);苔蘚蟲素(bryostatin);卡利斯他汀(callystatin);CC-1065,包括其合成類似物阿多來新(adozelesin)、卡折來新(carzelesin)及比折來新(bizelesin);念珠藻素(cryptophycin),尤其係念珠藻素1及念珠藻素8;多拉斯他汀(dolastatin);多卡米星(duocarmycin),包括合成類似物KW-2189及CBI-TMI;艾榴塞洛素(eleutherobin);5-氮胞苷;水鬼蕉鹼(pancratistatin);匍枝珊瑚醇(sarcodictyin);海綿抑制素(spongistatin);氮芥,例如氮芥苯丁酸、萘氮芥(chlornaphazine)、環磷醯胺、葡磷醯胺、艾伏磷醯胺(evofosfamide)、苯達莫司汀(bendamustine)、雌氮芥(estramustine)、異環磷醯胺、甲基二氯乙基胺(mechlorethamine)、甲基二氯乙基胺氧化物鹽酸鹽、美法侖(melphalan)、新氮芥(novembichin)、膽甾醇對苯乙酸氮芥(phenesterine)、潑尼莫司汀(prednimustine)、曲磷胺(trofosfamide)及尿嘧啶氮芥;亞硝基脲,例如卡莫司汀(carmustine)、氯脲菌素(chlorozotocin)、福莫司汀(foremustine)、洛莫司汀(lomustine)、尼莫司汀(nimustine)及雷莫司汀(ranimustine);抗生素,例如烯二炔抗生素(例如,卡奇黴素(calicheamicin),尤其係卡奇黴素γII及卡奇黴素φ I1);達內黴素(dynemicin),包括達內黴素A;雙膦酸鹽,例如氯膦酸(clodronate)、埃斯波黴素(esperamicin)、新制癌菌素發色團(neocarzinostatin chromophore)及相關色蛋白烯二炔抗生素發色團、阿克拉黴素(aclacinomycin)、放線菌素(actinomycin)、安麯黴素(authramycin)、偶氮絲胺酸、博萊黴素(bleomycins)、c放線菌素(cactinomycin)、卡拉黴素(carabicin)、洋紅黴素(carrninomycin)、嗜癌黴素(carzinophilin)、色黴素 (chromomycin)、放線菌素D(dactinomycin)、道諾黴素(daunorubicin)、地托比星(detorubicin)、6-重氮基-5-側氧基-L-正白胺酸、多柔比星(doxorubicin)(包括嗎啉基-多柔比星、氰基嗎啉基-多柔比星、2-吡咯啉基-多柔比星及去氧多柔比星)、泛艾黴素(epirubicin)、依索比星(esorubicin)、伊達比星(idarubicin)、麻西羅黴素(marcellomycin)、絲裂黴素(例如絲裂黴素C)、黴酚酸(mycophenolic acid)、諾拉黴素(nogalamycin)、橄欖黴素(olivomycin)、培洛黴素(peplomycin)、泊非黴素(porfiromycin)、嘌呤黴素(puromycin)、三鐵阿黴素(quelamycin)、羅多比星(rodorubicin)、鏈黑黴素(streptonigrin)、鏈脲黴素、殺結核菌素(tubercidin)、烏苯美司(ubenimex)、淨司他汀(zinostatin)及佐柔比星(zorubicin);抗代謝物,例如胺甲喋呤(methotrexate)及5-氟尿嘧啶(5-fluorouracil)(5-FU);葉酸類似物,例如二甲葉酸(demopterin)、胺甲喋呤、蝶羅呤(pteropterin)及三甲曲沙(trimetrexate);嘌呤類似物,例如氟達拉濱(fludarabine)、6-巰嘌呤、硫咪嘌呤(thiamiprine)及硫鳥嘌呤;嘧啶類似物,例如安西他濱(ancitabine)、阿紮胞苷(azacitidine)、6-氮雜尿苷(6-azauridine)、卡莫氟(carmofur)、阿糖胞苷、二去氧尿苷、去氧氟尿苷(doxifluridine)、依諾他濱(enocitabine)及氟尿苷(floxuridine);雄激素,例如卡普睪酮(calusterone)、丙酸屈他雄酮(dromostanolone propionate)、環硫雄醇(epitiostanol)、美雄烷(mepitiostane)及睪內酯(testolactone);抗腎上腺素,例如胺魯米特(aminoglutethimide)、米托坦(mitotane)及曲洛司坦(trilostane);葉酸補充劑,例如亞葉酸;放射性治療劑,例如鐳-223;單端孢黴烯(trichothecene),尤其係T-2毒素、疣皰菌素A(verracurin A)、桿孢菌素(roridin A)及蛇形菌素(anguidine);類紫杉醇(taxoid),例如太平洋紫杉醇(paclitaxel)(TAXOL®)、亞伯杉烷、多西他賽(TAXOTERE®)、卡巴他賽(cabazitaxel)、BIND-014;鉑類似物,例如順鉑及卡鉑、NC-6004奈米鉑(nanoplatin);醋葡醛內酯(aceglatone);醛磷醯胺醣苷(aldophosphamide glycoside);胺基乙醯丙酸(aminolevulinic acid);恩尿嘧啶 (eniluracil);安吖啶;黑斯特氮芥(hestrabucil);比生群(bisantrene);依達曲沙(edatraxate);地磷醯胺(defosfamine);秋水仙胺(demecolcine);地吖醌(diaziquone);依氟鳥胺酸(elformthine);依利醋銨(elliptinium acetate);埃博黴素(epothilone);依託格魯(etoglucid);硝酸鎵;羥基脲;香菇多醣(lentinan);甲醯四氫葉酸(leucovorin);氯尼達明(lonidainine);類美登素(maytansinoid),例如美登素(maytansine)及安絲菌素(ansamitocin);米托胍腙(mitoguazone);米托蒽醌;莫哌達醇(mopidamol);硝胺丙吖啶(nitracrine);噴司他汀(pentostatin);蛋胺氮芥(phenamet);吡柔比星(pirarubicin);洛索蒽醌(losoxantrone);氟嘧啶;醛葉酸;鬼臼酸;2-乙基醯肼;丙卡巴肼(procarbazine);多醣-K(PSK);雷佐生(razoxane);利索新(rhizoxin);西左非蘭(sizofiran);鍺螺胺(spirogermanium);替奴佐酸(tenuazonic acid);曲貝替定(trabectedin)、三亞胺醌(triaziquone);2,2',2"-三氯三乙胺;烏拉坦(urethane);長春地辛(vindesine);達卡巴嗪(dacarbazine);甘露莫司汀(mannomustine);二溴甘露醇(mitobronitol);二溴衛矛醇(mitolactol);哌泊溴烷(pipobroman);加賽特辛(gacytosine);阿糖胞苷(arabinoside)(「Ara-C」);環磷醯胺;噻替派;氮芥苯丁酸;吉西他濱(gemcitabine)(GEMZAR®);6-硫鳥嘌呤;巰嘌呤;胺甲喋呤;長春鹼(vinblastine);鉑;依託泊苷(etoposide)(VP-16);異環磷醯胺(ifosfamide);米托蒽醌(mitroxantrone);長春新鹼(vancristine);長春瑞濱(vinorelbine)(NAVELBINE®);能滅瘤(novantrone);替尼泊苷(teniposide);依達曲沙(edatrexate);道諾黴素(daunomycin);胺蝶呤(aminopterin);截瘤達(xeoloda);伊班膦酸鹽(ibandronate);CPT-11;拓樸異構酶抑制劑RFS 2000;二氟甲基鳥胺酸(DMFO);類視色素,例如視黃酸;卡培他濱(capecitabine);NUC-1031;FOLFIRI(氟尿嘧啶、甲醯四氫葉酸及伊立替康);及上述藥劑中任一者之醫藥學上可接受之鹽、酸或衍生物。「化學治療劑」之定義中亦包括抗激素劑,例如抗雌激素及選擇性雌激素受體調節劑(SERM)、酶芳香酶之抑制劑、 抗雄激素劑及上述藥劑中任一者之醫藥學上可接受之鹽、酸或衍生物,其用於調控或抑制對腫瘤之激素作用。抗雌激素及SERM之實例包括(例如)他莫昔芬(tamoxifen)(包括NOLVADEXTM)、雷洛昔芬(raloxifene)、屈洛昔芬(droloxifene)、4-羥基他莫昔芬、曲沃昔芬(trioxifene)、可莫昔芬(keoxifene)、LY117018、奧那司酮(onapristone)及托瑞米芬(toremifene)(FARESTON®)。酶芳香酶之抑制劑調控腎上腺中之雌激素產生。實例包括4(5)-咪唑、胺魯米特、乙酸甲地孕酮(MEGACE®)、依西美坦(exemestane)、福美坦(formestane)、法曲唑(fadrozole)、伏氯唑(vorozole)(RIVISOR®)、來曲唑(FEMARA®)及阿那曲唑(ARIMIDEX®)。抗雄激素之實例包括阿帕魯醯胺(apalutamide)、阿比特龍(abiraterone)、恩雜魯胺(enzalutamide)、氟他胺(flutamide)、蓋樂特龍(galeterone)、尼魯米特(nilutamide)、比卡魯胺(bicalutamide)、柳培林(leuprolide)、戈舍瑞林(goserelin)、ODM-201、APC-100、ODM-204。助孕酮受體拮抗劑之實例包括奧那司酮。
抗血管生成劑包括(但不限於)類視色素酸及其衍生物、2-甲氧基雌二醇、ANGIOSTATIN®、ENDOSTATIN®、瑞格菲尼(regorafenib)、奈卡帕拉尼(necuparanib)、舒拉明(suramin)、角鯊胺(squalamine)、金屬蛋白酶-1之組織抑制劑、金屬蛋白酶-2之組織抑制劑、纖維蛋白溶酶原活化劑抑制劑-1、纖維蛋白溶酶原活化劑抑制劑-2、軟骨源抑制劑、太平洋紫杉醇(白蛋白結合型紫杉醇)、血小板因子4、硫酸魚精蛋白(鯡精蛋白)、硫酸化幾丁質衍生物(自雪花蟹外殼製備)、硫酸化多醣肽聚醣複合物(sp-pg)、星狀孢菌素、基質代謝調節劑,包括例如脯胺酸類似物(例如(1-氮雜環丁烷-2-甲酸(LACA)、順羥基脯胺酸、d,I-3,4-脫氫脯胺酸、硫脯胺酸、α,α'-二吡啶基、β-胺基丙腈富馬酸鹽、4-丙基-5-(4-吡啶基)-2(3h)-噁唑酮、胺甲喋呤、米托蒽醌、肝素、干擾素、2巨球蛋白-血清、金屬蛋白酶之雞抑制劑-3(ChIMP-3)、糜蛋白酶抑制素、β-環糊精十四硫酸鹽、依匹黴素(eponemycin)、菸麴黴素(fumagillin)、硫代蘋果酸金鈉、d-青黴胺、β-1-抗膠原酶 -血清、α-2-抗纖維蛋白溶酶、比生群、氯苯紮利二鈉(lobenzarit disodium)、n-2-羧基苯基-4-氯鄰胺基苯甲酸二鈉或「CCA」、沙利竇邁(thalidomide);血管生成抑制類固醇、羧基胺基咪唑(cargboxynaminolmidazole);金屬蛋白酶抑制劑,例如BB-94,S100A9之抑制劑(例如他喹莫德(tasquinimod))。其他抗血管生成劑包括針對該等血管生成生長因子之抗體、較佳單株抗體:β-FGF、α-FGF、FGF-5、VEGF同種型、VEGF-C、HGF/SF及Ang-1/Ang-2。
抗纖維變性劑包括(但不限於)諸如β-胺基丙腈(BAPN)等化合物以及關於離胺醯基氧化酶之抑制劑及其在治療與膠原之異常沈積相關之疾病及病況中之用途之美國專利第4,965,288號及關於抑制LOX用於治療各種病理性纖維變性狀態之化合物之美國專利第4,997,854號中揭示之化合物,該等案件以引用方式併入本文中。其他實例性抑制劑闡述於關於諸如2-異丁基-3-氟-、氯-或溴-烯丙基胺等化合物之美國專利第4,943,593號、關於2-(1-萘基氧基甲基)-3-氟烯丙基胺之美國專利第5,021,456號、第5,059,714號、第5,120,764號、第5,182,297號及第5,252,608號及美國公開專利申請案第2004/0248871號中,該等案件以引用方式併入本文中。實例性抗纖維變性劑亦包括與離胺醯氧化酶之活性位點之羰基反應之一級胺,且更具體而言在與羰基結合後產生藉由共振穩定之產物之彼等,例如以下一級胺:乙烯胺、肼、苯基肼及其衍生物;胺基脲及脲衍生物;胺基腈,例如BAPN或2-硝基乙胺;不飽和或飽和鹵代胺,例如2-溴-乙胺、2-氯乙胺、2-三氟乙胺、3-溴丙基胺及對-鹵代苄基胺;及硒基高半胱胺酸內酯。其他抗纖維變性劑係銅螯合劑,其穿透或不穿透細胞。實例性化合物包括阻斷源自離胺醯基及羥基離胺醯基殘基由離胺醯氧化酶之氧化脫胺之醛衍生物的間接抑制劑。實例包括硫醇胺、具體而言D-青黴胺及其類似物,例如2-胺基-5-巰基-5-甲基己酸、D-2-胺基-3-甲基-3-((2-乙醯胺基乙基)二硫基)丁酸、對-2-胺基-3-甲基-3-((2-胺基乙基)二硫基)丁酸、4-((對-1-二甲基-2-胺基-2-羧基乙基)二硫基) 丁烷硫酸鈉、2-乙醯胺基乙基-2-乙醯胺基乙烷硫醇硫酸鹽及4-巰基丁烷亞硫酸鈉三水合物。
免疫治療劑包括且不限於適於治療患者之治療性抗體。治療性抗體之實例包括阿巴伏單抗(abagovomab)、ABP-980、阿德木單抗(adecatumumab)、阿福圖珠單抗(afutuzumab)、阿倫單抗(alemtuzumab)、阿托珠單抗(altumomab)、阿麥妥昔單抗(amatuximab)、麻安莫單抗(anatumomab)、阿西莫單抗(arcitumomab)、巴維昔單抗(bavituximab)、貝妥莫單抗(bectumomab)、貝伐珠單抗(bevacizumab)、比伐單抗(bivatuzumab)、布利莫單抗(blinatumomab)、貝倫妥單抗、坎妥珠單抗(cantuzumab)、卡妥索單抗(catumaxomab)、CC49、西妥昔單抗(cetuximab)、西他珠單抗(citatuzumab)、西妥木單抗(cixutumumab)、克立瓦妥珠單抗(clivatuzumab)、可那木單抗(conatumumab)、達西珠單抗(dacetuzumab)、達洛珠單抗(dalotuzumab)、達雷木單抗(daratumumab)、地莫單抗(detumomab)、地努圖希單抗(dinutuximab)、卓齊妥單抗(drozitumab)、度利戈妥單抗(duligotumab)、杜昔妥單抗(dusigitumab)、依美昔單抗(ecromeximab)、埃羅妥珠單抗(elotuzumab)、艾米拜土珠單抗(emibetuzumab)、恩司昔單抗(ensituximab)、厄馬索單抗(ertumaxomab)、埃達珠單抗(etaracizumab)、法利珠單抗(farletuzumab)、芬克拉妥珠單抗(ficlatuzumab)、芬妥木單抗(figitumumab)、弗蘭托單抗(flanvotumab)、弗妥昔單抗(futuximab)、蓋尼塔單抗(ganitumab)、吉妥珠單抗(gemtuzumab)、吉瑞妥昔單抗(girentuximab)、格萊木單抗(glembatumumab)、替伊莫單抗(ibritumomab)、伊戈伏單抗(igovomab)、英加妥珠單抗(imgatuzumab)、英達妥昔單抗(indatuximab)、伊珠單抗(inotuzumab)、英妥木單抗(intetumumab)、伊匹單抗(ipilimumab)(YERVOY®、MDX-010、BMS-734016及MDX-101)、伊妥木單抗(iratumumab)、拉貝珠單抗(labetuzumab)、來沙木單抗(lexatumumab)、林妥珠單抗(lintuzumab)、洛伏珠單抗、魯卡木單抗(lucatumumab)、馬帕木單抗 (mapatumumab)、馬妥珠單抗(matuzumab)、米拉珠單抗、明瑞莫單抗(minretumomab)、米妥莫單抗(mitumomab)、莫格木里單抗(mogamulizumab)、莫妥莫單抗(moxetumomab)、那莫單抗(naptumomab)、納那妥單抗(narnatumab)、奈昔木單抗(necitumumab)、尼妥珠單抗(nimotuzumab)、諾非單抗(nofetumomab)、OBI-833、奧妥珠單抗、奧卡妥珠單抗(ocaratuzumab)、奧法木單抗(ofatumumab)、奧拉妥單抗(olaratumab)、昂妥珠單抗(onartuzumab)、莫奧珠單抗(oportuzumab)、奧戈伏單抗(oregovomab)、帕尼單抗(panitumumab)、帕圖珠單抗(parsatuzumab)、帕蘇德托(pasudotox)、帕圖單抗(patritumab)、帕圖莫單抗(pemtumomab)、帕妥珠單抗(pertuzumab)、平妥單抗(pintumomab)、普托木單抗(pritumumab)、拉妥木單抗(racotumomab)、拉圖單抗(radretumab)、雷莫蘆單抗(ramucirumab)(Cyramza®)、利妥木單抗(rilotumumab)、利妥昔單抗(rituximab)、羅妥木單抗(robatumumab)、沙馬珠單抗(samalizumab)、沙妥莫單抗(satumomab)、西羅珠單抗(sibrotuzumab)、司妥昔單抗、索利圖單抗(solitomab)、司妥佐單抗(simtuzumab)、他妥珠單抗(tacatuzumab)、他妥莫單抗(taplitumomab)、替妥莫單抗(tenatumomab)、替普莫單抗(teprotumumab)、替加珠單抗(tigatuzumab)、托西莫單抗(tositumomab)、曲妥珠單抗、托卡珠單抗(tucotuzumab)、烏比利單抗(ubilituximab)、維妥珠單抗(veltuzumab)、沃妥珠單抗(vorsetuzumab)、沃圖莫單抗(votumumab)、紮魯木單抗(zalutumumab)、3F8及諸如此類。利妥昔單抗可用於治療惰性B細胞癌,包括邊緣區淋巴瘤、WM、CLL及小淋巴球性淋巴瘤。利妥昔單抗與化學治療劑之組合尤其有效。所例示治療性抗體可進一步經放射性同位素粒子(例如銦-111、釔-90(90Y-克立瓦妥珠單抗)或碘-131)標記或與其組合。應理解,上述試劑、分子、化合物或抗體可具有額外機制方式且將不限於上述方式;例如,化學治療劑可為抗纖維變性劑。
提供本文所述化合物(I)之鹽或共晶體形式用於製造藥物產品之用途。 本文所述化合物(I)之鹽或共晶體形式可用作製造過程中之中間體以產生藥物產品。
可製備包含本文所述化合物(I)之鹽或共晶體形式且調配於一或多種醫藥學上可接受之載劑、賦形劑或其他成分之組合物,將其放置於適當容器中,且標記用於治療適應病症。因此,亦涵蓋製品,例如包含本文所述化合物(I)之鹽或共晶體形式之劑型及含有化合物之使用說明之標記的容器。
在一些實施例中,製品係包含本文所述化合物(I)之鹽或共晶體形式及一或多種醫藥學上可接受之載劑、賦形劑或其他成分之劑型的容器。在本文所述製品之一個實施例中,劑型係錠劑。
亦涵蓋套組。舉例而言,套組可包含醫藥組合物之劑型及含有組合物在治療醫學病況中之使用說明書之包裝插頁。套組中之使用說明書可為針對治療BTK介導之病症,包括(例如)自體免疫疾病或癌症。在某些實施例中,標記上適應之病況可包括(例如)自體免疫疾病或癌症之治療。
提供以下實例以進一步有助於理解申請案中揭示之實施例,且預料彼等熟習實例所屬領域技術者熟知之習用方法的理解。下文闡述之特定物質及條件意欲例示本文揭示之實施例之特定態樣且不應理解為限制其合理範疇。
藉由各種分析技術(包括X射線粉末繞射圖案(XRPD)、差示掃描量熱法(DSC)及熱重分析(TGA))使用下述程序表徵6-胺基-9-[(3R)-1-(2-丁炔醯基)-3-吡咯啶基]-7-(4-苯氧基苯基)-7,9-二氫-8H-嘌呤-8-酮之鹽及共晶體形式。
X射線粉末繞射(XRPD):於環境條件下在以下實驗設置下利用PAN分析型XPERT-PRO繞射儀收集XRPD圖案:45KV,40mA,Kα1=1.5406Å,掃描範圍2°至40°,步長0.0084°或0.0167°,量測時間:5min。
差示掃描量熱法(DSC):利用配備有50位置取樣器之TA儀器Q2000系統收集DSC溫度記錄圖。使用合乎標準之銦實施能量及溫度之校正。通常將針紮孔之鋁盤中之1-5mg每一樣品以10℃/min自25℃加熱至300℃。貫穿量測在樣品上維持50mL/min之乾燥氮之吹掃。熔融吸熱之起始報告為熔點。
熱重分析(TGA):利用配備有25位置取樣器之TA儀器Q5000系統收集TGA溫度記錄圖。通常將1-5mg每一樣品裝載至預稱重之鋁盤上並以10℃/min自25℃加熱至250℃。貫穿量測在樣品上維持25mL/min之氮吹掃。
動態氣相吸附(DVS):利用TA儀器Q5000SA系統收集用於測定固體之吸濕性之DVS數據。將溫度控制腔室設定於25℃下且以10mL/min之流速引入乾燥氮。將約1至5mg樣品放置於半球形金屬塗佈之石英坩堝或可棄式鋁盤中。藉由將腔室中之相對濕度(RH)以10%增量自10%控制至90%、接著控制至10%以完成完全吸附/解吸循環來執行25℃下之逐步等溫線實驗。
於約40℃下將5g化合物(I)游離鹼溶解於約50mL乙腈中。將540mg硫酸用約10mL乙腈稀釋,並經約2.5h裝入化合物(I)溶液中。在添加期間形成漿液。其後,將漿液加熱至約70℃且經約2h冷卻至約0℃。過濾混合物,用約10mL乙腈洗滌,且在真空下於約50℃下在烘箱中乾燥過夜。獲得5.05g化合物(I)半硫酸鹽。
將100mg化合物(I)及19.8mg草酸之混合物溶解於丙酮中且於大約室溫下攪拌過夜。形成漿液且藉由XRPD確認為化合物(I)草酸鹽以產生晶種批料。藉由於約20℃下將10g化合物(I)及2g草酸溶解於約50mL丙酮中、之後添加晶種批料之種晶來製備批料。形成漿液且在約2h內裝入約50mL正庚烷。 過濾混合物,用10mL丙酮洗滌且在真空下於約50℃下乾燥。獲得10.7g化合物(I)草酸鹽。
將100mg化合物(I)與24.9mg乙烷-1,2-二磺酸二水合物之混合物在約1mL乙腈、四氫呋喃或丙酮或其混合物中混合。將混合物於大約室溫下攪拌過夜。過濾漿液並在真空下於約50℃下乾燥。藉由XRPD檢查固體以確認化合物(I)半乙二磺酸鹽之形成。
將100mg化合物(I)與49.8mg乙烷-1,2-二磺酸二水合物之混合物在約1mL乙腈、四氫呋喃或丙酮或其混合物中混合。在使用乙腈時,實施加晶種(晶種來自使用此段落中所述之四氫呋喃或丙酮之實驗)。將混合物在室溫下攪拌過夜。過濾漿液並在真空下於約50℃下乾燥。藉由XRPD檢查固體以確認化合物(I)乙二磺酸鹽之形成。
將108.7mg化合物(I)、43.1mg(0.5eq)萘-1,5-二磺酸及約1.5mL乙腈之混合物在密封之4mL琥珀玻璃小瓶中超音波處理約30分鐘。將樣品於約50℃下藉由磁力攪拌棒攪動約1小時,且接著冷卻至室溫,其中樣品保持攪拌約5天。藉由離心分離固體且於約50℃下在真空下乾燥過夜。1H NMR顯示約一半當量之萘-1,5-二磺酸及一些殘餘乙腈。於約125℃下進一步乾燥樣品。
將100.4mg化合物(I)、26.2mg(1eq)富馬酸及0.75mL乙酸異丙酯之混合物在密封之4mL琥珀玻璃小瓶中超音波處理約30分鐘。將樣品於約50℃下藉由磁力攪拌棒攪動約1小時,且接著冷卻至室溫,其中樣品保持攪拌約2週。藉由離心分離固體且於約50℃下在真空下乾燥過夜。1H NMR顯示約1當 量之富馬酸。
藉由於約50℃下將500mg化合物(I)及127.7mg(1eq)富馬酸在5mL乙酸異丙酯及0.5mL水之混合物中攪拌約16小時且接著於室溫下攪拌約2天製備另一批料。過濾樣品,用5mL乙酸異丙酯洗滌並在真空下於約50℃下乾燥過夜。固體之XRPD分析顯示與上述實驗中之樣品相同之圖案。
將99.5mg化合物(I)、27.1mg(1eq)琥珀酸及0.75mL乙酸異丙酯之混合物在密封之4mL琥珀玻璃小瓶中超音波處理約30分鐘。將樣品於約50℃下藉由磁力攪拌棒攪動約1小時,且接著冷卻至室溫,其中樣品保持攪拌約1週。藉由離心分離固體且於約50℃下在真空下乾燥過夜。1H NMR顯示約1當量之琥珀酸。
藉由於室溫下將500mg化合物(I)及129.9mg(1eq)琥珀酸在5mL乙酸異丙酯中攪拌約3天製備另一批料。過濾樣品,用5mL乙酸異丙酯洗滌並在真空下於約50℃下乾燥過夜。固體之XRPD分析顯示與上述實驗中之樣品相同之圖案。
Claims (48)
- 一種化合物(I)之半硫酸鹽,
- 如申請專利範圍第1項之化合物(I)半硫酸鹽,其中X射線粉末繞射圖包含6.6、18.6及23.7°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測定。
- 如申請專利範圍第2項之化合物(I)半硫酸鹽,其中該繞射圖進一步包含7.1及13.7°2θ±0.2°之峰。
- 如申請專利範圍第2項或第3項之化合物(I)半硫酸鹽,其中另外,差示掃描量熱曲線包含約192℃下之吸熱。
- 一種化合物(I)之草酸鹽,
- 如申請專利範圍第5項之化合物(I)草酸鹽,其中X射線粉末繞射圖包含7.2、18.2及23.3°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測 定。
- 如申請專利範圍第6項之化合物(I)草酸鹽,其中該繞射圖進一步包含13.8及20.2°2θ±0.2°之峰。
- 如申請專利範圍第6項或第7項之化合物(I)草酸鹽,其中另外,差示掃描量熱曲線包含約171℃下之吸熱。
- 一種化合物(I)之半乙二磺酸鹽,
- 如申請專利範圍第9項之化合物(I)半乙二磺酸鹽,其中X射線粉末繞射圖包含5.9、11.8及17.6°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測定。
- 如申請專利範圍第10項之化合物(I)半乙二磺酸鹽,其中該繞射圖進一步包含21.2及23.6°2θ±0.2°之峰。
- 如申請專利範圍第10項或第11項之化合物(I)半乙二磺酸鹽,其中另外,差示掃描量熱曲線包含約165℃下之吸熱。
- 一種化合物(I)之乙二磺酸鹽,
- 如申請專利範圍第13項之化合物(I)乙二磺酸鹽,其中X射線粉末繞射圖包含5.7、16.6及24.2°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測定。
- 如申請專利範圍第14項之化合物(I)乙二磺酸鹽,其中該繞射圖進一步包含11.1及22.2°2θ±0.2°之峰。
- 如申請專利範圍第14項或第15項之化合物(I)乙二磺酸鹽,其中另外,差示掃描量熱曲線包含約154℃下之吸熱。
- 一種化合物(I)之半萘二磺酸鹽,
- 如申請專利範圍第17項之化合物(I)半萘二磺酸鹽,其中X射線粉末繞射圖包含15.5、16.5及23.8°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測定。
- 如申請專利範圍第18項之化合物(I)半萘二磺酸鹽,其中該繞射 圖進一步包含5.6及20.3°2θ±0.2°之峰。
- 如申請專利範圍第18項或第19項之化合物(I)半萘二磺酸鹽,其中另外,差示掃描量熱曲線包含約180℃下之吸熱。
- 一種化合物(I)之富馬酸鹽,
- 如申請專利範圍第21項之化合物(I)富馬酸鹽,其中X射線粉末繞射圖包含13.0、16.6及19.9°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測定。
- 如申請專利範圍第22項之化合物(I)富馬酸鹽,其中該繞射圖進一步包含8.3及19.0°2θ±0.2°之峰。
- 如申請專利範圍第22項或第23項之化合物(I)富馬酸鹽,其中另外,差示掃描量熱曲線包含約158℃下之吸熱。
- 一種化合物(I)之琥珀酸鹽,
- 如申請專利範圍第25項之化合物(I)琥珀酸鹽,其中X射線粉末繞射圖包含13.2、16.5及18.0°2θ之峰(±0.2°),如利用繞射儀使用Cu-Kα輻射所測定。
- 如申請專利範圍第26項之化合物(I)琥珀酸鹽,其中該繞射圖進一步包含8.2及18.6°2θ±0.2°之峰。
- 如申請專利範圍第26項或第27項之化合物(I)琥珀酸鹽,其中另外,差示掃描量熱曲線包含約142℃下之吸熱。
- 一種醫藥組合物,其包含醫藥學上可接受之載劑及一或多種選自由以下組成之群之化合物:如申請專利範圍第1項至第4項中任一項之化合物(I)之半硫酸鹽、如申請專利範圍第5項至第8項中任一項之化合物(I)之草酸鹽、如申請專利範圍第9項至第12項中任一項之化合物(I)之半乙二磺酸鹽、如申請專利範圍第13項至第16項中任一項之化合物(I)之乙二磺酸鹽、如申請專利範圍第17項至第20項中任一項之化合物(I)之半萘二磺酸鹽、如申請專利範圍第21項至第24項中任一項之化合物(I)之富馬酸鹽以及如申請專利範圍第25項至第28項中任一項之化合物(I)之琥珀酸鹽。
- 一種治療有需要之人類之至少部分由布魯頓氏酪胺酸激酶(Bruton's Tyrosine Kinase,BTK)介導之疾病的方法,其包含投與治療有效量之如申請專利範圍第1項至第4項中任一項之化合物(I)之半硫酸鹽、如申請專利範圍第5項至第8項中任一項之化合物(I)之草酸鹽、如申請專利範圍第9項至第12項中任一項之化合物(I)之半乙二磺酸鹽、如申請專利範圍第13項至第16項中任一項之化合物(I)之乙二磺酸鹽、如申請專利範圍第17項至第20項中任一項之化合物(I)之半萘二磺酸鹽、如申請專利範圍第21項至第24項中任一項之化合物(I)之富馬酸鹽、如申請專利範圍第25項至第28項中任一項之化合物(I)之琥珀酸鹽或如申請專利範圍第29項之醫藥組合物。
- 如申請專利範圍第30項之方法,其中該疾病係選自癌症、血液惡性病、白血病、淋巴瘤、骨髓增生性病症、骨髓發育不良症候群、漿細胞腫瘤、實體腫瘤、發炎、纖維化、自體免疫病症、過敏病況、過敏、心血管疾病、神經退化疾病、腎病症、病毒感染、肥胖症及自體免疫疾病。
- 一種由以下物質抑制布魯頓氏酪胺酸激酶之活性的方法:如申請專利範圍第1項至第4項中任一項之化合物(I)之半硫酸鹽、如申請專利範圍第5項至第8項中任一項之化合物(I)之草酸鹽、如申請專利範圍第9項至第12項中任一項之化合物(I)之半乙二磺酸鹽、如申請專利範圍第13項至第16項中任一項之化合物(I)之乙二磺酸鹽、如申請專利範圍第17項至第20項中任一項之化合物(I)之半萘二磺酸鹽、如申請專利範圍第21項至第24項中任一項之化合物(I)之富馬酸鹽、如申請專利範圍第25項至第28項中任一項之化合物(I)之琥珀酸鹽或如申請專利範圍第29項之醫藥組合物。
- 一種套組,其包含如申請專利範圍第1項至第13項中任一項之化合物或如申請專利範圍第14項之醫藥組合物或進行使用之標記及/或說明書。
- 一種如申請專利範圍第1項至第29項中任一項之化合物或醫藥組合物的用途,其用於製造用於治療如申請專利範圍第30項至第31項中任一項之疾病或病況的藥劑。
- 一種製造如申請專利範圍第1項至第4項中任一項之化合物(I)之半硫酸鹽的方法,其包含使化合物(I)與硫酸接觸。
- 如申請專利範圍第35項之方法,其中該接觸包含以下步驟:i)將化合物(I)與該硫酸組合於適宜溶劑中以獲得混合物;ii)將步驟i)中獲得之該混合物加熱至約70℃;iii)將步驟ii)中獲得之該混合物冷卻至約0℃;及 iv)收集步驟iii)中獲得之固體材料以獲得該化合物(I)之半硫酸鹽。
- 一種製造如申請專利範圍第5項至第8項中任一項之化合物(I)之草酸鹽的方法,其包含使化合物(I)與草酸接觸。
- 如申請專利範圍第37項之方法,其中該接觸包含以下步驟:i)於室溫下將化合物(I)及該草酸溶解於適宜溶劑中以獲得混合物;及ii)收集步驟i)中獲得之固體材料以獲得該化合物(I)之草酸鹽。
- 一種製造如申請專利範圍第9項至第12項中任一項之化合物(I)之半乙二磺酸鹽的方法,其包含使化合物(I)與乙烷-1,2-二磺酸二水合物接觸。
- 如申請專利範圍第39項之方法,其中該接觸包含以下步驟:i)於室溫下將化合物(I)與該乙烷-1,2-二磺酸二水合物組合於適宜溶劑中以獲得混合物;及ii)收集步驟i)中獲得之固體材料以獲得該化合物(I)之半乙二磺酸鹽。
- 一種製造如申請專利範圍第13項至第16項中任一項之化合物(I)之乙二磺酸鹽的方法,其包含使化合物(I)與乙烷-1,2-二磺酸二水合物接觸。
- 如申請專利範圍第41項之方法,其中該接觸包含以下步驟:i)於室溫下將化合物(I)與該乙烷-1,2-二磺酸二水合物組合於適宜溶劑中以獲得混合物;及ii)收集步驟i)中獲得之固體材料以獲得該化合物(I)之乙二磺酸鹽。
- 一種製造如申請專利範圍第17項至第20項中任一項之化合物(I)之半萘二磺酸鹽的方法,其包含使化合物(I)與萘-1,5-二磺酸接觸。
- 如申請專利範圍第43項之方法,其中該接觸包含以下步驟:i)將化合物(I)與該萘-1,5-二磺酸組合於適宜溶劑中以獲得混合物;ii)將步驟i)中獲得之該混合物加熱至約50℃; iii)將步驟ii)中獲得之該混合物冷卻至室溫;及iv)收集步驟iii)中獲得之固體材料以獲得該化合物(I)之半萘二磺酸鹽。
- 一種製造如申請專利範圍第21項至第24項中任一項之化合物(I)之富馬酸鹽的方法,其包含使化合物(I)與富馬酸接觸。
- 如申請專利範圍第45項之方法,其中該接觸包含以下步驟:i)將化合物(I)與該富馬酸組合於適宜溶劑中;ii)將步驟i)中獲得之該混合物加熱至約50℃;iii)將步驟ii)中獲得之該混合物冷卻至室溫;及iv)收集步驟iii)中獲得之固體材料以獲得該化合物(I)之富馬酸鹽。
- 一種製造如申請專利範圍第25項至第28項中任一項之化合物(I)之琥珀酸鹽的方法,其包含使化合物(I)與琥珀酸接觸。
- 如申請專利範圍第47項之方法,其中該接觸包含以下步驟:i)將化合物(I)與該琥珀酸組合於適宜溶劑中;ii)將步驟i)中獲得之該混合物加熱至約50℃;iii)將步驟ii)中獲得之該混合物冷卻至室溫;及iv)收集步驟iii)中獲得之固體材料以獲得該化合物(I)之琥珀酸鹽。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762463429P | 2017-02-24 | 2017-02-24 | |
US62/463,429 | 2017-02-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201831489A true TW201831489A (zh) | 2018-09-01 |
TWI754011B TWI754011B (zh) | 2022-02-01 |
Family
ID=61617129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107106216A TWI754011B (zh) | 2017-02-24 | 2018-02-23 | 布魯頓氏酪胺酸激酶之抑制劑 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10370381B2 (zh) |
EP (1) | EP3585788A1 (zh) |
JP (1) | JP7014811B2 (zh) |
KR (1) | KR102362646B1 (zh) |
CN (1) | CN110312720A (zh) |
AR (1) | AR110998A1 (zh) |
AU (1) | AU2018224136B2 (zh) |
CA (1) | CA3054403A1 (zh) |
TW (1) | TWI754011B (zh) |
WO (1) | WO2018156895A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI762939B (zh) * | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202108160YA (en) * | 2019-01-29 | 2021-08-30 | Huya Bioscience International Llc | Sulcardine salts |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2786996A (en) * | 1952-01-04 | 1957-03-26 | Todd William | Wave measuring system |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
MX2009010284A (es) | 2007-03-28 | 2010-01-29 | Pharmacyclics Inc | Inhibidores de la tirosina-cinasa de bruton. |
EP2537529B1 (en) | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
US8080544B2 (en) | 2008-02-05 | 2011-12-20 | Merck Sharp & Dohme Corp. | Prodrugs of CGRP receptor antagonists |
US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
CN103370080A (zh) | 2010-02-04 | 2013-10-23 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
RS55184B1 (sr) | 2010-05-31 | 2017-01-31 | Ono Pharmaceutical Co | Derivat purinona kao inhibitor btk kinaze |
PE20131376A1 (es) | 2010-08-27 | 2013-11-25 | Gilead Biologics Inc | Anticuerpos para metaloproteinasa-9 de matriz |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
SI3689878T1 (sl) | 2011-07-19 | 2021-12-31 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci |
EP2734523A1 (en) | 2011-07-19 | 2014-05-28 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
WO2013027802A1 (ja) | 2011-08-23 | 2013-02-28 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ddr1抗体 |
GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
CN104024257A (zh) | 2011-10-04 | 2014-09-03 | 吉利德卡利斯托加有限责任公司 | Pi3k的新的喹喔啉抑制剂 |
HUE031094T2 (en) | 2011-11-29 | 2017-07-28 | Ono Pharmaceutical Co | Purinone derivative hydrochloride |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
AR092662A1 (es) | 2012-09-24 | 2015-04-29 | Gilead Sciences Inc | Anticuerpos anti-ddr1 |
US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
CA2895782C (en) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
JP6207100B2 (ja) | 2012-12-21 | 2017-10-04 | ギリアード カリストガ エルエルシー | イソキノリノンまたはキナゾリノンホスファチジルイノシトール3−キナーゼ阻害剤 |
WO2014152114A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
NZ714710A (en) | 2013-06-14 | 2016-11-25 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
JP6458018B2 (ja) | 2013-07-02 | 2019-01-23 | ファーマサイクリックス エルエルシー | キナーゼ阻害剤としてのプリノン化合物 |
MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
US9937171B2 (en) * | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
-
2018
- 2018-02-23 TW TW107106216A patent/TWI754011B/zh not_active IP Right Cessation
- 2018-02-23 AU AU2018224136A patent/AU2018224136B2/en not_active Ceased
- 2018-02-23 WO PCT/US2018/019422 patent/WO2018156895A1/en unknown
- 2018-02-23 CA CA3054403A patent/CA3054403A1/en active Pending
- 2018-02-23 KR KR1020197024651A patent/KR102362646B1/ko active IP Right Grant
- 2018-02-23 CN CN201880012910.8A patent/CN110312720A/zh active Pending
- 2018-02-23 US US15/903,285 patent/US10370381B2/en not_active Expired - Fee Related
- 2018-02-23 AR ARP180100432A patent/AR110998A1/es unknown
- 2018-02-23 JP JP2019545987A patent/JP7014811B2/ja active Active
- 2018-02-23 EP EP18710221.5A patent/EP3585788A1/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI762939B (zh) * | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
Also Published As
Publication number | Publication date |
---|---|
EP3585788A1 (en) | 2020-01-01 |
JP7014811B2 (ja) | 2022-02-01 |
AR110998A1 (es) | 2019-05-22 |
JP2020508325A (ja) | 2020-03-19 |
US20180251464A1 (en) | 2018-09-06 |
KR102362646B1 (ko) | 2022-02-11 |
WO2018156895A1 (en) | 2018-08-30 |
AU2018224136B2 (en) | 2021-10-21 |
TWI754011B (zh) | 2022-02-01 |
KR20190120211A (ko) | 2019-10-23 |
CN110312720A (zh) | 2019-10-08 |
CA3054403A1 (en) | 2018-08-30 |
WO2018156895A8 (en) | 2019-09-26 |
US10370381B2 (en) | 2019-08-06 |
AU2018224136A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI732245B (zh) | Pd‐1/pd‐l1抑制劑 | |
TWI639427B (zh) | Tank-結合激酶抑制劑化合物 | |
TW201942117A (zh) | Pd‐1/pd‐l1抑制劑 | |
US10314844B2 (en) | Inhibitors of Bruton's tyrosine kinase | |
TWI778443B (zh) | Mcl1抑制劑 | |
CN106459005A (zh) | 磷脂酰肌醇3‑激酶抑制剂 | |
US20180141939A1 (en) | Solid forms of a bet inhibitor | |
TW202110832A (zh) | 經取代之烯吲哚酮化物及其用途 | |
TWI754011B (zh) | 布魯頓氏酪胺酸激酶之抑制劑 | |
TW202005654A (zh) | 2,2,─環二核苷酸 | |
TWI834442B (zh) | Ikaros鋅指家族降解劑及其用途 | |
WO2023147418A1 (en) | Parp7 inhibitors | |
US20230183216A1 (en) | Pyridizin-3(2h)-one derivatives | |
TW202334118A (zh) | Ikaros鋅指家族降解劑及其用途 | |
TW202346277A (zh) | Ikaros鋅指家族降解劑及其用途 | |
TW202400138A (zh) | Kras g12d調節化合物 | |
TW202010503A (zh) | 3’3’-環二核苷酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |